KR20180037650A - A composition for producing metal nanoparticles comprising black ginseng extracts and the use thereof - Google Patents
A composition for producing metal nanoparticles comprising black ginseng extracts and the use thereof Download PDFInfo
- Publication number
- KR20180037650A KR20180037650A KR1020160127842A KR20160127842A KR20180037650A KR 20180037650 A KR20180037650 A KR 20180037650A KR 1020160127842 A KR1020160127842 A KR 1020160127842A KR 20160127842 A KR20160127842 A KR 20160127842A KR 20180037650 A KR20180037650 A KR 20180037650A
- Authority
- KR
- South Korea
- Prior art keywords
- nanoparticles
- metal nanoparticles
- metal
- composition
- gold
- Prior art date
Links
- 239000002082 metal nanoparticle Substances 0.000 title claims abstract description 92
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 235000020710 ginseng extract Nutrition 0.000 title claims description 22
- 238000000034 method Methods 0.000 claims abstract description 36
- 238000004519 manufacturing process Methods 0.000 claims abstract description 27
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 19
- 241000208340 Araliaceae Species 0.000 claims abstract description 13
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 13
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 13
- 239000000284 extract Substances 0.000 claims abstract description 13
- 235000008434 ginseng Nutrition 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 239000002105 nanoparticle Substances 0.000 claims description 98
- 239000010931 gold Substances 0.000 claims description 95
- 229910052737 gold Inorganic materials 0.000 claims description 94
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 93
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 claims description 92
- -1 salt compound Chemical class 0.000 claims description 40
- 229910052751 metal Inorganic materials 0.000 claims description 23
- 239000002184 metal Substances 0.000 claims description 23
- 239000002537 cosmetic Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 239000007795 chemical reaction product Substances 0.000 claims description 11
- 239000002243 precursor Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 9
- 230000003064 anti-oxidating effect Effects 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 6
- 235000013402 health food Nutrition 0.000 claims description 6
- 238000006722 reduction reaction Methods 0.000 claims description 6
- 241000588722 Escherichia Species 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 101710134784 Agnoprotein Proteins 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 241000191940 Staphylococcus Species 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 229910003771 Gold(I) chloride Inorganic materials 0.000 claims description 2
- FDWREHZXQUYJFJ-UHFFFAOYSA-M gold monochloride Chemical compound [Cl-].[Au+] FDWREHZXQUYJFJ-UHFFFAOYSA-M 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 abstract description 21
- 239000003963 antioxidant agent Substances 0.000 abstract description 7
- 239000003381 stabilizer Substances 0.000 abstract description 5
- 239000003638 chemical reducing agent Substances 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 description 37
- 230000015572 biosynthetic process Effects 0.000 description 28
- 235000013305 food Nutrition 0.000 description 26
- 238000004458 analytical method Methods 0.000 description 18
- 239000000243 solution Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000036541 health Effects 0.000 description 12
- 239000002245 particle Substances 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 230000000844 anti-bacterial effect Effects 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 230000035484 reaction time Effects 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000002149 energy-dispersive X-ray emission spectroscopy Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 238000002296 dynamic light scattering Methods 0.000 description 7
- 229910052709 silver Inorganic materials 0.000 description 7
- 239000004332 silver Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 6
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 235000013376 functional food Nutrition 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 238000013507 mapping Methods 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000002441 X-ray diffraction Methods 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 230000009759 skin aging Effects 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 244000018764 Nyssa sylvatica Species 0.000 description 3
- 235000003339 Nyssa sylvatica Nutrition 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 230000007760 free radical scavenging Effects 0.000 description 3
- 229940074391 gallic acid Drugs 0.000 description 3
- 235000004515 gallic acid Nutrition 0.000 description 3
- 229940107131 ginseng root Drugs 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 229920002230 Pectic acid Polymers 0.000 description 2
- 229920000265 Polyparaphenylene Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000205160 Pyrococcus Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 241000607598 Vibrio Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000000783 alginic acid Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Chemical class 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 2
- 239000010318 polygalacturonic acid Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 150000005168 4-hydroxybenzoic acids Chemical class 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- JAJIPIAHCFBEPI-UHFFFAOYSA-N 9,10-dioxoanthracene-1-sulfonic acid Chemical class O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2S(=O)(=O)O JAJIPIAHCFBEPI-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 1
- 238000005169 Debye-Scherrer Methods 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000208680 Hamamelis mollis Species 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- RZPAKFUAFGMUPI-UHFFFAOYSA-N Oleandomycin Natural products O1C(C)C(O)C(OC)CC1OC1C(C)C(=O)OC(C)C(C)C(O)C(C)C(=O)C2(OC2)CC(C)C(OC2C(C(CC(C)O2)N(C)C)O)C1C RZPAKFUAFGMUPI-UHFFFAOYSA-N 0.000 description 1
- 239000004104 Oleandomycin Substances 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- JQXXHWHPUNPDRT-YOPQJBRCSA-N chembl1332716 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CCN(C)CC1 JQXXHWHPUNPDRT-YOPQJBRCSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 229910000423 chromium oxide Inorganic materials 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000007973 glycine-HCl buffer Substances 0.000 description 1
- 150000002343 gold Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- BDRTVPCFKSUHCJ-UHFFFAOYSA-N molecular hydrogen;potassium Chemical compound [K].[H][H] BDRTVPCFKSUHCJ-UHFFFAOYSA-N 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 229960002950 novobiocin Drugs 0.000 description 1
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- RZPAKFUAFGMUPI-KGIGTXTPSA-N oleandomycin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C RZPAKFUAFGMUPI-KGIGTXTPSA-N 0.000 description 1
- 229960002351 oleandomycin Drugs 0.000 description 1
- 235000019367 oleandomycin Nutrition 0.000 description 1
- 238000004204 optical analysis method Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 238000007626 photothermal therapy Methods 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical class [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- SDVHRXOTTYYKRY-UHFFFAOYSA-J tetrasodium;dioxido-oxo-phosphonato-$l^{5}-phosphane Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)P([O-])([O-])=O SDVHRXOTTYYKRY-UHFFFAOYSA-J 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- 239000011882 ultra-fine particle Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 229940118846 witch hazel Drugs 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 229940057977 zinc stearate Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/242—Gold; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/20—Ingredients acting on or related to the structure
- A23V2200/25—Nanoparticles, nanostructures
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
Abstract
Description
본 발명은 흑삼 추출물을 포함하는 금속 나노입자 제조용 조성물 및 이의 용도에 관한 것으로, 보다 구체적으로, 본 발명은 흑삼 추출물을 유효성분으로 포함하는 금속 나노입자 제조용 조성물, 상기 조성물을 이용한 금속 나노입자의 제조방법, 상기 방법에 의해 제조된 금속 나노입자, 및 상기 금속 나노입자의 항균 및 항산화 용도에 관한 것이다. The present invention relates to a composition for the preparation of metal nanoparticles comprising black ginseng extract and a use thereof. More specifically, the present invention relates to a composition for the preparation of metal nanoparticles comprising black ginseng extract as an active ingredient, Methods, metal nanoparticles produced by the method, and antimicrobial and antioxidant uses of the metal nanoparticles.
금속 나노입자는 입자 크기의 분포가 균일하고, 표면의 개질이 쉬우며, 우수한 안정성을 나타내는 등의 구체적이고 특별한 특징 덕분에 다양한 과학 분야 특히, 의생명과학 및 공학 분야에서 많은 관심을 받고 있다(Mody VV, J. Pharm. Bioall. Sci., 2010;2:282.; Moritz M, Chem. Eng. J., 2013;228:596-613.; Iravani S. ISRN., 2014;2014.). 특히, 의료 분야에서는 나노스케일의 자기를 이용한 의료영상 및 바이오센서, 유전자 타겟 및 약물 전달 등에 적용된다.Metal nanoparticles have attracted much attention in various scientific fields, especially in life sciences and engineering fields, due to their specific and specific features such as uniform particle size distribution, easy surface modification, and excellent stability (Mody VV, J. Pharm. Bioall. Sci., 2010; 2: 282 .; Moritz M, Chem. Eng J., 2013; 228: 596-613 .; Iravani S. ISRN., 2014; Especially, in medical field, it is applied to medical image, biosensor, gene target and drug delivery using nanoscale magnetism.
여러 금속 중에서, 은은 우수한 항균 특성을 나타냄에 따라 세균 감염의 치료에 주로 사용되어 왔다. 나노입자 형태로서의 은 나노입자는 그의 이온 형태보다 세포독성이 감소하고 항박테리아의 효과를 증대시킨다고 알려져 있어, 항균, 항염증 또는 감염 방지를 위해 많은 분야에 적용된다. 금 또한, 그것의 독특한 표면 플라즈몬 진동으로 약물 전달체, 포토 광열 치료(photo thermal therap), 검체에서 병원균의 면역 색층 확인(immune chromatographic identification), 바이오센서, DNA 표지 등의 다양한 분야에 활용되어 왔다. 또한, 금속 나노입자는 우수한 생체적합성을 나타내며, 입자 표면을 변형하기 쉽고, 세포 투과성이 높기 때문에 약물 담체(drug carrier)로서의 이용이 기대되고 있다(Narsireddy Amreddy et,al., International Journal of Nanomedicine 2015:10 6773-6788, Jean-Pascal Piret et,al., Nanoscale, 2012, 4, 7168-7184). Among the various metals, silver has been used primarily in the treatment of bacterial infections as it exhibits excellent antibacterial properties. Silver nanoparticles in the form of nanoparticles are known to reduce cytotoxicity and increase the effect of antibacterial agents over their ionic forms, and thus they are applied to many fields for antibacterial, anti-inflammatory or infectious prevention. Gold has also been utilized in a variety of fields, including drug delivery, photo thermal therapies, immune chromatographic identification of pathogens in specimens, biosensors, and DNA markers, with its unique surface plasmon vibrations. In addition, metal nanoparticles exhibit excellent biocompatibility and are expected to be used as drug carriers because they are easily deformed and have high cell permeability (Narsireddy Amreddy et al., International Journal of Nanomedicine 2015: 10 6773-6788, Jean-Pascal Piret et al., Nanoscale, 2012, 4, 7168-7184).
일반적으로 금속 나노입자의 제조에는 화학적 합성방법, 물리적 제조방법 등이 이용되고 있으며, 화학적 합성방법은 비교적 공정이 간단하나 비용이 많이 들고 시약의 독성 등이 문제시 되고 있다. 또한, 물리적 방법은 나노입자의 크기를 제어하기 어렵고, 고가의 제조 설비가 요구되는 등의 문제점 때문에 효과적인 금속 나노입자의 제조가 어렵다는 단점이 있다.Generally, chemical synthesis methods and physical production methods are used for the production of metal nanoparticles. The chemical synthesis method is relatively simple, but the cost is high and the toxicity of the reagent is problematic. In addition, physical methods have the disadvantage that it is difficult to control the size of nanoparticles, and it is difficult to produce effective metal nanoparticles because of the problems such as requiring expensive manufacturing facilities.
이러한 이유로, 최근 박테리아 또는 균주에 의한 제조방법이나, 천연 추출물을 유효성분으로 포함하는 친환경적인 금속 나노입자의 제조방법에 대한 연구가 많이 진행되고 있다. 그러나, 종래 박테리아 또는 균주에 의해 금속 나노입자를 합성하는 방법은 짧게는 하루에서 길게는 며칠까지 합성을 위한 긴 시간이 필요하고, 합성된 나노입자의 안정화를 위해 부가적인 환원제 또는 안정화제와 같은 캡핑제(capping agent)가 필요하다는 단점이 존재하였다. 이에, 여전히 친환경적이면서 동시에 안정하고, 화학적 또는 물리적인 합성방법과 비교할 때 제조시간의 한계를 극복한 금속 나노입자에 대한 개발은 계속 요구되고 있는 실정이다.For this reason, researches on a method for producing environmentally friendly metal nanoparticles containing a natural extract as an active ingredient have been extensively studied. However, conventional methods for synthesizing metal nanoparticles by bacteria or strains require a long time for synthesis from days to days to several days. In order to stabilize the synthesized nanoparticles, a cap such as an additional reducing agent or a stabilizer There is a disadvantage that a capping agent is required. Therefore, development of metal nanoparticles overcoming the manufacturing time limit is still required as compared with a synthetic method which is still environmentally friendly, stable, chemical, or physical.
이러한 배경하에, 본 발명자들은 보다 효과적으로 금속 나노입자를 제조할 수 있는 방법을 개발하고자 예의 연구 노력한 결과, 흑삼 추출물을 사용할 경우, 항균 및 항산화 활성을 나타내는 금속 나노입자를 제조할 수 있음을 확인하고, 본 발명을 완성하였다.Under these circumstances, the inventors of the present invention have made extensive efforts to develop a method for producing metal nanoparticles more effectively. As a result, it has been confirmed that metal nanoparticles exhibiting antimicrobial and antioxidative activities can be prepared using black ginseng extract, Thus completing the present invention.
본 발명의 하나의 목적은 흑삼 추출물을 유효성분으로 포함하는, 금속 나노입자 제조용 조성물을 제공하는 것이다.It is an object of the present invention to provide a composition for preparing metal nanoparticles, which comprises black ginseng extract as an active ingredient.
본 발명의 다른 목적은 상기 금속 나노입자 제조용 조성물과 금속 전구체를 반응시키는 단계를 포함하는, 금속 나노입자의 제조방법을 제공하는 것이다. Another object of the present invention is to provide a method for producing metal nanoparticles, which comprises reacting the metal nanoparticle-forming composition with a metal precursor.
본 발명의 또 다른 목적은 상기 제조방법에 의해 제조된 금속 나노입자를 제공하는 것이다. Still another object of the present invention is to provide the metal nanoparticles produced by the above-mentioned production method.
본 발명의 또 다른 목적은 상기 금속 나노입자를 포함하는 항균 조성물을 제공하는 것이다.It is still another object of the present invention to provide an antimicrobial composition comprising the metal nanoparticles.
본 발명의 또 다른 목적은 상기 금속 나노입자를 포함하는 항산화용 약학 조성물을 제공하는 것이다.Yet another object of the present invention is to provide a pharmaceutical composition for antioxidation comprising the metal nanoparticles.
본 발명의 또 다른 목적은 상기 금속 나노입자를 포함하는 항산화용 건강식품 조성물을 제공하는 것이다.It is still another object of the present invention to provide an antioxidant health food composition comprising the metal nanoparticles.
본 발명의 또 다른 목적은 상기 금속 나노입자를 포함하는 항산화용 가능성화장료 조성물을 제공하는 것이다.It is still another object of the present invention to provide a cosmetic composition for antioxidation comprising the metal nanoparticles.
상술한 목적을 달성하기 위한 일 실시양태로서, 본 발명은 흑삼 추출물을 유효성분으로 포함하는, 금속 나노입자 제조용 조성물을 제공한다.As one embodiment for achieving the above-mentioned object, the present invention provides a composition for the production of metal nanoparticles comprising black ginseng extract as an active ingredient.
본 발명의 금속 나노입자 제조용 조성물은 천연 추출물인 흑삼 추출물을 유효성분으로 포함하여, 별도의 환원제 또는 안정제의 부가 없이도 크기가 균일한 금속 나노입자를 제조하는데 사용할 수 있다. The composition for preparing metal nanoparticles of the present invention can be used for preparing metal nanoparticles of uniform size without addition of a reducing agent or a stabilizer, which contains black ginseng extract as an active ingredient.
본 발명의 용어, "흑삼 추출물"은 특별히 이에 제한되지 않으나, 하기 방법에 의해 제조된 것일 수 있다:The term "black ginseng extract" of the present invention is not particularly limited, but may be prepared by the following method:
1) 흑삼에 추출용매를 가하여 추출하는 단계;1) extracting black ginseng by adding an extraction solvent;
2) 단계 1)의 추출물을 식힌 후 여과하는 단계; 및2) cooling the extract of step 1) and filtering; And
3) 단계 2)의 여과한 추출물을 감압 농축한 후 건조하는 단계.3) Concentrating the filtered extract of step 2) under reduced pressure and drying.
상기 방법에 있어서, 단계 1)의 흑삼은 백삼을 가공하여 제조한 것 또는 시판되는 것 등 제한 없이 사용할 수 있다. 상기 백삼을 가공하여 흑삼을 제조하는 경우, 백삼을 찌고 말리는 과정을 다수 반복하여 흑삼을 제조할 수 있는데, 상기 백삼을 찌고 말리는 과정의 반복회수는 특별히 이에 제한되지 않으나, 일 예로서, 7 내지 9회를 반복할 수 있고, 다른 예로서, 9회를 반복할 수 있다.In the above method, the black gins of step 1) can be used without limitation, such as those prepared by processing white ginseng or commercially available ones. When the white ginseng is processed to produce black ginseng, black ginseng can be produced by repeating a process of sowing and drying white ginseng. The number of repetitions of the step of grinding and drying the white ginseng is not particularly limited. For example, 7 to 9 As another example, it is possible to repeat 9 times.
상기 방법에 있어서, 상기 추출용매는 흑삼 추출물을 제조할 수 있는 한 특별히 이에 제한되지 않으나, 물, C1 내지 C4의 알코올 또는 이들의 혼합물을 사용할 수 있으며, 구체적으로는 에탄올, 메탄올 또는 물을 사용할 수 있고, 보다 구체적으로는 50% 에탄올 또는 물을 사용할 수 있다.In the above method, the extraction solvent is not particularly limited as long as it can produce black ginseng extract, but water, C1 to C4 alcohols or a mixture thereof can be used. Specifically, ethanol, methanol or water can be used And more specifically 50% ethanol or water.
상기 방법에 있어서, 추출 방법으로는 여과법, 열수추출, 침지추출, 환류냉각추출 및 초음파추출 등 당업계의 통상적인 방법을 이용할 수 있다. 상기 추출용매는 흑삼에 0.1 내지 10배 첨가할 수 있으며, 구체적으로는 0.3 내지 5배 첨가할 수 있으나, 이에 제한되지 않는다. 또한, 추출온도는 구체적으로 20℃ 내지 150℃일 수 있으나, 이에 제한되지 않으며, 추출시간은 구체적으로 1분 내지 3시간일 수 있으나, 이에 제한되지 않는다.In the above method, conventional methods such as filtration, hot water extraction, immersion extraction, reflux cooling extraction and ultrasonic extraction can be used as the extraction method. The extraction solvent may be added in an amount of 0.1 to 10 times, preferably 0.3 to 5 times, to black ginseng, but is not limited thereto. In addition, the extraction temperature may be specifically 20 ° C to 150 ° C, but is not limited thereto, and the extraction time may be specifically 1 minute to 3 hours, but is not limited thereto.
상기 방법에 있어서, 단계 3)의 감압농축은 구체적으로 진공감압농축기 또는 진공회전증발기를 이용할 수 있으나, 이에 제한되지 않으며, 상기 건조는 구체적으로 감압건조, 진공건조, 비등건조, 분무건조 또는 동결 건조할 수 있으나, 이에 제한되지 않는다.In the above method, the vacuum concentration of the step 3) may be carried out by using a vacuum decompression concentrator or a vacuum rotary evaporator, but the present invention is not limited thereto. Specifically, the drying may be performed under reduced pressure, vacuum, boiling, spray drying, But is not limited thereto.
본 발명의 용어, "금속 나노입자"는 금속으로 이루어진, 크기가 1~100nm인 초미세 입자로, 작은 크기에 기인하는 특이하고도 다양한 성질을 보이는 입자를 의미한다. 본 발명에서 금속 나노입자는 제조방법에 따라 서로 다른 생리활성을 가질 수 있으며, 구체적으로 흑삼 추출물을 이용하여 제조된 본 발명의 금속 나노입자는 상기 추출물의 생리활성 물질을 포함하고 있어, 다른 방법으로 제조된 금속 나노입자보다 매우 우수한 생물학적 활성을 가질 수 있다.The term "metal nanoparticle" in the present invention means an ultra-fine particle having a size of 1 to 100 nm, which is made of metal, and exhibits a specific and diverse nature due to its small size. In the present invention, the metal nanoparticles may have different physiological activities depending on the production method. Specifically, the metal nanoparticles of the present invention prepared using the black ginseng extract include a physiologically active substance of the extract, It can have a much better biological activity than the prepared metal nanoparticles.
구체적으로, 상기 "금속"은 금(Au) 또는 은(Ag)일 수 있으나, 이에 제한되는 것은 아니다.Specifically, the "metal" may be gold (Au) or silver (Ag), but is not limited thereto.
본 발명에서, 흑삼 추출물을 이용하여 제조된 금 나노입자는 '금 나노입자' 또는 'Sg-AuNP(s)'로 혼용되어 사용할 수 있고, 은 나노입자는 '은 나노입자' 또는 'Sg-AgNP(s)'로 혼용되어 사용될 수 있다.In the present invention, gold nanoparticles prepared using black ginseng extract may be used in combination as' gold nanoparticles' or 'Sg-AuNP (s)', and silver nanoparticles may be used as' silver nanoparticles' or 'Sg- (s) '.
다른 실시양태로서, 본 발명은 상기 금속 나노입자 제조용 조성물과 금속 전구체를 반응시키는 단계를 포함하는, 금속 나노입자의 제조방법을 제공한다.In another embodiment, the present invention provides a method for producing metal nanoparticles, comprising the step of reacting the metal nanoparticle-forming composition with a metal precursor.
본 발명에서 제공하는 금속 나노입자의 제조방법은 천연 추출물인 흑삼 추출물을 이용하기 때문에 종래의 화학적 합성방법 및 물리적 합성방법에 비해 친환경적이고, 동시에 별도의 환원제 또는 안정제 없이 안정화를 유지할 수 있는 금속 나노입자를 제조할 수 있으므로, 다양한 산업 분야에서 매우 유용하게 사용될 수 있다. Since the method for producing metal nanoparticles according to the present invention uses the extract of black ginseng, which is a natural extract, it is more environmentally friendly than the conventional chemical synthesis method and physical synthesis method, and the metal nanoparticles It can be very usefully used in various industrial fields.
본 발명의 용어, "금속 전구체"는 금속 나노입자를 제조하기 위하여 첨가하는 화합물을 의미한다. 상기 금속 전구체는 환원반응에 의하여 금속 나노입자를 형성할 수 있는 한 특별히 이에 제한되지 않으나, 일 예로서, 환원반응에 의하여 금속 나노입자를 형성할 수 있는 금속염 화합물이 될 수 있다. The term "metal precursor" of the present invention means a compound added to prepare metal nanoparticles. The metal precursor is not particularly limited as long as it can form metal nanoparticles by a reduction reaction. For example, the metal precursor may be a metal salt compound capable of forming metal nanoparticles by a reduction reaction.
예를 들어, 금속 나노입자 중에서 금을 주재로 포함하는 금 나노입자를 제조할 경우에는, 상기 금속 전구체의 일 예로서, 환원반응에 의해 금 나노입자를 형성할 수 있는 테트라클로로금(III)산(HAuCl4), NaAuCl3, AuCl3 등의 금염 화합물을 사용할 수 있고, 다른 예로서, 테트라클로로금(III)산(HAuCl4)을 사용할 수 있다.For example, in the case of producing gold nanoparticles containing gold as a main component in metal nanoparticles, as an example of the metal precursor, tetrachloro gold (III) acid capable of forming gold nanoparticles by a reduction reaction (HAuCl 4 ), NaAuCl 3 , AuCl 3, and the like. As another example, tetrachloro gold (III) acid (HAuCl 4 ) can be used.
또한, 금속 나노입자 중에서 은을 주재로 포함하는 은 나노입자를 제조할 경우에는, 상기 금속 전구체의 일 예로서, 환원반응에 의해 은 나노입자를 형성할 수 있는 AgBF4, AgCF3SO3, AgClO4, AgNO3, AgPF6, Ag(CF3COO) 등의 은염 화합물을 사용할 수 있고, 다른 예로서, 질산은(AgNO3)을 사용할 수 있다.In the case of producing silver nanoparticles containing silver as a main component in the metal nanoparticles, examples of the metal precursor include AgBF 4 , AgCF 3 SO 3 and AgClO 4 capable of forming silver nanoparticles by a reduction reaction 4 , AgNO 3 , AgPF 6 , and Ag (CF 3 COO). As another example, silver nitrate (AgNO 3 ) can be used.
본 발명의 제조방법에서, 상기 금속 전구체의 농도는 금속 나노입자를 제조할 수 있는 한 이에 제한되지 않으나, 0.01 내지 100 mM, 구체적으로 0.01 내지 50 mM, 더욱 구체적으로 0.01 내지 10 mM일 수 있다. In the production method of the present invention, the concentration of the metal precursor may be 0.01 to 100 mM, specifically 0.01 to 50 mM, more specifically 0.01 to 10 mM, as long as it can produce metal nanoparticles.
또한, 본 발명의 제조방법에서, 반응 온도는 금속 나노입자를 제조할 수 있는 한 이에 제한되지 않으나, 10 내지 100℃, 구체적으로 금속이 금인 경우에 반응 온도는 80℃ 이상, 더욱 구체적으로 80 내지 90℃가 될 수 있고; 금속이 은인 경우에 반응 온도는 반응 온도는 60℃ 이상, 더욱 구체적으로 60 내지 90℃가 될 수 있다.In addition, in the production method of the present invention, the reaction temperature is not limited as long as the metal nanoparticles can be produced, but the reaction temperature is preferably 80 ° C or higher, more specifically 80 ° C or higher, 90 < 0 >C; When the metal is silver, the reaction temperature may be 60 占 폚 or higher, more specifically 60 to 90 占 폚.
또한, 본 발명의 제조방법에서, 반응 시간이 증가할수록 제조된 금속 나노입자의 수준이 증가하지만, 금속 나노입자에 따라 차이가 있다. 일 예로서, 금 나노입자의 경우에는 구체적으로 1분 내지 1시간, 더욱 구체적으로 10 내지 25분이 될 수 있고, 은 나노입자의 경우에는 구체적으로 30분 내지 7시간, 더욱 구체적으로 4.5 내지 5시간이 될 수 있다.In addition, in the production method of the present invention, as the reaction time increases, the level of the prepared metal nanoparticles increases, but the difference is dependent on the metal nanoparticles. As an example, in the case of gold nanoparticles, it may be from 1 minute to 1 hour, more specifically from 10 to 25 minutes, in the case of silver nanoparticles, specifically from 30 minutes to 7 hours, more specifically from 4.5 to 5 hours .
본 발명의 제조방법은 상기 반응이 종료된 후, 반응물을 원심분리하여 금속 나노입자를 회수하는 단계를 추가로 포함할 수 있다.The method of the present invention may further include the step of recovering the metal nanoparticles by centrifuging the reaction product after the reaction is completed.
또 다른 실시양태로서, 본 발명은 상기 제조방법에 의해 제조된 금속 나노입자를 제공한다. In another embodiment, the present invention provides the metal nanoparticles produced by the above-mentioned production method.
본 발명의 금속 나노입자는 의료용, 생물학적 분석용, 연료용, 전자부품 재료의 용도로 사용될 수 있다. 이에 제한되지 않지만, 구체적으로, 금 나노입자는 고유의 빛 전도 특성으로 인해 유기태양전지, 센서프로브, 생물의학용 약물 전달체, 전도재료 및 촉매제로 이용될 수 있고, 은 나노입자는 광학특성, 전도성 및 항균성으로 인해, 항균제, 정량검출을 위한 바이오센서, 광학분석법 등에 이용될 수 있다. 또한, 본 발명의 금속 나노입자는 크기나 형태, 표면의 화학적 특성 또는 응집상태를 변화시킴으로써, 입자의 광학적, 전자적 특정을 조절할 수 있다.The metal nanoparticles of the present invention can be used for medical, biological analysis, fuel, and electronic component materials. Specifically, gold nanoparticles can be used as an organic solar cell, a sensor probe, a biological drug delivery system, a conductive material and a catalyst, due to inherent light conduction characteristics, and silver nanoparticles have optical properties, And antibacterial properties, it can be used as an antibacterial agent, a biosensor for quantitative detection, an optical analysis method, and the like. In addition, the metal nanoparticles of the present invention can control the optical and electronic characteristics of the particles by changing the size, shape, chemical characteristics of the surface, or aggregation state.
본 발명의 제조방법에 의해 제조된 금속 나노입자의 모양은, 일반적으로 구형의 모양을 띨 수 있으나, 이에 제한되는 것은 아니다.The shape of the metal nanoparticles produced by the method of the present invention may be generally spherical, but is not limited thereto.
본 발명의 제조방법에 의해 제조된 금속 나노입자의 결정의 크기는 5 내지 30 nm, 구체적으로 금속이 금인 경우에 3 내지 7 nm, 더욱 구체적으로 5 nm 일 수 있고; 금속이 은인 경우에 5 내지 10 nm, 더욱 구체적으로 8 nm일 수 있다.The size of the crystals of the metal nanoparticles produced by the production method of the present invention may be 5 to 30 nm, more specifically 3 to 7 nm, more specifically 5 nm when the metal is gold; And may be from 5 to 10 nm, more specifically 8 nm, when the metal is silver.
아울러, 상기 금속 나노입자는 실온에서 상이한 조건의 pH 조건에 방치한 경우에도, 안정적으로 유지되었으므로, 생물학적으로 안정한 물질임을 확인하였다.In addition, it was confirmed that the metal nanoparticles were biologically stable because they were stably maintained even when they were left at pH conditions under different conditions at room temperature.
또 다른 실시양태로서, 본 발명은 상기 금속 나노입자를 포함하는, 항균용 조성물을 제공한다.In another embodiment, the present invention provides an antimicrobial composition comprising the metal nanoparticles.
이때, "금속 나노입자"는 상기에서 설명한 바와 같다.Here, the "metal nanoparticles" are as described above.
본 발명의 금속 나노입자는 병원성 미생물에 대해 우수한 항균 활성을 가지므로, 이를 포함하는 조성물은 다양한 산업에 매우 유용하게 활용될 수 있다.Since the metal nanoparticles of the present invention have an excellent antibacterial activity against pathogenic microorganisms, the composition containing the metal nanoparticles can be very usefully utilized in various industries.
본 발명의 항균용 조성물은 세균, 진균 또는 효모에 대해 항균활성을 가질 수 있으며, 구체적으로 비브리오(Vibrio) 속, 살모넬라(Salmonella) 속, 스테피로코커스(Staphylococcus) 속, 에스케리치아(Escherichia) 속, 바실러스(Bacillus) 속 및 칸디다(Candida) 속 미생물로 이루어진 군에서 선택되는 하나 이상에 대해 항균 활성을 가질 수 있으며, 더욱 구체적으로, 스테피로코커스(Staphylococcus) 속 미생물 또는 에스케리치아(Escherichia) 속 미생물, 더더욱 구체적으로 황색포도상구균(Staphylococcus aureus) 및 대장균(Escherichia coli)에 대해 항균 활성을 가질 수 있으나, 이에 제한되지 않는다. The antimicrobial composition of the present invention may have an antimicrobial activity against bacteria, fungi or yeast, in particular Vibrio (Vibrio) genus, Salmonella (Salmonella), A stacking Pyrococcus (Staphylococcus), An Escherichia (Escherichia) in Bacillus (Bacillus) genus and Candida (Candida) may have an antimicrobial activity for at least one selected from the group consisting of a microorganism of the genus, more specifically, stearyl Pyrococcus (Staphylococcus) in microorganisms or Escherichia (Escherichia) in Microorganisms, more specifically Staphylococcus aureus and Escherichia coli coli ), but is not limited thereto.
또한, 본 발명의 항균용 조성물은 린코마이신 (lincomycin), 올레안도마이신 (oleandomycin), 노보비오신 (novobiocin), 반코마이신 (vancomycin), 페니실린G (penicillin G) 및 리팜피신 (rifampicin)으로 이루어진 군에서 선택되는 하나 이상의 항생제를 추가로 포함할 수 있다. In addition, the antimicrobial composition of the present invention is selected from the group consisting of lincomycin, oleandomycin, novobiocin, vancomycin, penicillin G, and rifampicin Lt; RTI ID = 0.0 > antibiotics < / RTI >
금속 나노입자와 항생제를 함께 처리할 경우, 금속 나노입자 또는 항생제 각각을 처리하는 것보다 병원성 미생물에 대해 우수한 항균 활성을 나타내는 바, 이를 포함하는 조성물은 다양한 산업에 매우 유용하게 활용될 수 있다.When the metal nanoparticles and the antibiotic are treated together, they exhibit an excellent antimicrobial activity against pathogenic microorganisms, rather than treating each of the metal nanoparticles or the antibiotic, and the composition containing the metal nanoparticles and the antibiotic can be very usefully utilized in various industries.
또 다른 실시양태로서, 본 발명은 상기 금속 나노입자를 포함하는, 항산화용 약학 조성물을 제공한다.In another embodiment, the present invention provides a pharmaceutical composition for antioxidation comprising the metal nanoparticles.
이때, "금속 나노입자"는 상기에서 설명한 바와 같다.Here, the "metal nanoparticles" are as described above.
본 발명의 용어, "항산화"는 유해한 프리라디칼(free radical)을 제거하는 것을 의미하며, 상기 프리라디칼에 의한 산화적 손상으로부터 세포를 보호하는 현상을 의미한다.The term "antioxidant" of the present invention refers to the removal of harmful free radicals, which means the protection of cells from oxidative damage by the free radicals.
본 발명의 제조방법에 의해 제조된 금속 나노입자는 항산화 활성을 나타내므로, 이들을 유효성분으로 포함하는 항산화용 약학 조성물은 활성산소로 인해 발생하는 질환들을 예방, 개선 및 치료하기 위한 목적으로 사용될 수 있다.Since the metal nanoparticles produced by the production method of the present invention exhibit antioxidative activity, antioxidant pharmaceutical compositions containing them as active ingredients can be used for the purpose of preventing, improving and treating diseases caused by active oxygen .
상기 활성산소로 인해 발생하는 질환들은 특별히 이에 제한되지는 않으나, 구체적으로 동맥경화증, 루게릭병, 파킨슨병, 알츠하이머, 근위축색경화증 및 헌팅톤병을 포함하는 퇴행성 신경질환, 심근경색, 협심증, 관상동맥질환, 허혈성 심장질환을 포함하는 심혈관 질환, 뇌졸중을 포함하는 허혈성 뇌질환, 당뇨병, 위염 및 위암을 포함하는 소화기계 질환, 노화, 암, 백혈병, 노화, 류마티스 관절염, 간염, 아토피성 피부염 등 다양한 질환을 포함할 수 있으며, 더욱 구체적으로 활성산소에 의해 발생되는 노화일 수 있다.The diseases caused by the active oxygen include, but are not limited to, degenerative neurological diseases including arteriosclerosis, Lou Gehrig's disease, Parkinson's disease, Alzheimer's disease, proximal axillary sclerosis and Huntington's disease, myocardial infarction, angina pectoris, coronary artery disease , Cardiovascular diseases including ischemic heart diseases, ischemic brain diseases including stroke, diabetes, gastrointestinal diseases including gastritis and gastric cancer, aging, cancer, leukemia, aging, rheumatoid arthritis, hepatitis and atopic dermatitis And more specifically may be aging caused by active oxygen.
또 다른 실시양태로서, 본 발명은 상기 금속 나노입자를 포함하는, 항산화용 건강식품 조성물을 제공한다.In another embodiment, the present invention provides a health food composition for antioxidation comprising the metal nanoparticles.
이때, "금속 나노입자"는 상기에서 설명한 바와 같다.Here, the "metal nanoparticles" are as described above.
본 발명의 제조방법에 의해 제조된 금 나노입자는 항산화 활성을 나타내므로, 활성산소로 인해 발생하는 질환의 예방 또는 개선을 도모할 수 있는 식품의 형태로 제조되어 섭취할 수 있다.The gold nanoparticles produced by the production method of the present invention exhibit an antioxidative activity and can be prepared and taken in the form of foods that can prevent or improve diseases caused by active oxygen.
본 발명의 용어, "식품"은 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올음료, 비타민 복합제, 건강기능식품 및 건강식품 등이 있으며, 통상적인 의미에서의 식품을 모두 포함한다.The term "food" of the present invention includes dairy products such as meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen and other noodles, gums, ice cream, various soups, drinks, tea, , A vitamin complex, a health functional food, and a health food, all of which include foods in a conventional sense.
상기 건강기능(성)식품(functional food)이란, 특정보건용 식품(food for special health use, FoSHU)와 동일한 용어로, 영양 공급 외에도 생체조절기능이 효율적으로 나타나도록 가공된 의학, 의료효과가 높은 식품을 의미한다. 여기서 "기능(성)"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건용도에 유용한 효과를 얻는 것을 의미한다. 본 발명의 식품은 당 업계에서 통상적으로 사용되는 방법에 의하여 제조가능하며, 상기 제조시에는 당 업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 또한 상기 식품의 제형 또한 식품으로 인정되는 제형이면 제한 없이 제조될 수 있다. 본 발명의 식품용 조성물은 다양한 형태의 제형으로 제조될 수 있으며, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나므로, 본 발명의 식품은 질병의 예방 또는 개선의 효과를 증진시키기 위한 보조제로 섭취가 가능하다.The term "functional food" as used herein is the same term as "food for special health use" (FoSHU). In addition to nutritional supplementation, functional foods are processed so as to efficiently show the biological control function, It means food. Here, the term "function (surname)" means that the structure and function of the human body have a beneficial effect for health use such as controlling nutrients or physiological action. The food of the present invention can be prepared by a method commonly used in the art and can be prepared by adding raw materials and ingredients which are conventionally added in the art. In addition, the formulations of the food can also be produced without restrictions as long as they are formulations recognized as food. The composition for food of the present invention can be manufactured in various formulations, and unlike general pharmaceuticals, it has an advantage that there is no side effect that may occur when a food is used as a raw material for a long period of taking a medicine, The food of the invention can be ingested as an adjuvant to promote the effect of preventing or ameliorating the disease.
상기 건강식품(health food)은 일반식품에 비해 적극적인 건강유지나 증진 효과를 가지는 식품을 의미하고, 건강보조식품(health supplement food)는 건강보조 목적의 식품을 의미한다. 경우에 따라, 건강 기능 식품, 건강식품, 건강보조식품의 용어는 호용된다.The health food refers to a food having an active health promotion effect or a health promotion effect compared to a general food, and a health supplement food refers to a health supplement food. In some cases, the terms health functional foods, health foods, and health supplements are used.
구체적으로, 상기 건강기능식품은 금속 나노입자를 음료, 차류, 향신료, 껌, 과자류 등의 식품소재에 첨가하거나, 캡슐화, 분말화, 현탁액 등으로 제조한 식품으로, 이를 섭취할 경우 건강상 특정한 효과를 가져오는 것을 의미하나, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용이 없는 장점이 있다.Specifically, the health functional food is a food prepared by adding metal nanoparticles to food materials such as beverage, tea, spice, gum and confectionery, or by encapsulation, powdering, suspension, etc., However, unlike general medicine, there is an advantage that there is no side effect that may occur when a food is used as a raw material for a long period of taking the medicine.
본 발명의 식품 조성물은 일상적으로 섭취하는 것이 가능하기 때문에 우수한 항산화 효과를 기대할 수 있어 매우 유용하다.Since the food composition of the present invention can be routinely ingested, an excellent antioxidative effect can be expected, which is very useful.
상기 조성물은 생리학적으로 허용 가능한 담체를 추가로 포함할 수 있는데, 담체의 종류는 특별히 제한되지 않으며 당해 기술 분야에서 통상적으로 사용되는 담체라면 어느 것이든 사용할 수 있다.The composition may further include a physiologically acceptable carrier. The carrier is not particularly limited and any carrier conventionally used in the art can be used.
또한, 상기 조성물은 식품 조성물에 통상 사용되어 냄새, 맛, 시각 등을 향상시킬 수 있는 추가 성분을 포함할 수 있다. 예들 들어, 비타민 A, C, D, E, B1, B2, B6, B12, 니아신(niacin), 비오틴(biotin), 폴레이트(folate), 판토텐산(panthotenic acid) 등을 포함할 수 있다. 또한, 아연(Zn), 철(Fe), 칼슘(Ca), 크롬(Cr), 마그네슘(Mg), 망간(Mn), 구리(Cu), 크륨(Cr) 등의 미네랄을 포함할 수 있다. 또한, 라이신, 트립토판, 시스테인, 발린 등의 아미노산을 포함할 수 있다. In addition, the composition may contain additional ingredients which are commonly used in food compositions and which can improve odor, taste, vision and the like. For example, vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, panthotenic acid and the like. In addition, it may include minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu) It may also include amino acids such as lysine, tryptophan, cysteine, valine, and the like.
또한, 상기 조성물은 방부제(소르빈산 칼륨, 벤조산나트륨, 살리실산, 데히드로초산나트륨 등), 살균제(표백분과 고도 표백분, 차아염소산나트륨 등), 산화방지제(부틸히드록시아니졸(BHA), 부틸히드록시톨류엔(BHT) 등), 착색제(타르색소 등), 발색제(아질산 나트륨, 아초산 나트륨 등), 표백제(아황산나트륨), 조미료(MSG 글루타민산나트륨 등), 감미료(둘신, 사이클레메이트, 사카린, 나트륨 등), 향료(바닐린, 락톤류 등), 팽창제(명반, D-주석산수소칼륨 등), 강화제, 유화제, 증점제(호료), 피막제, 검기초제, 거품억제제, 용제, 개량제 등의 식품 첨가물(food additives)을 포함할 수 있다. 상기 첨가물은 식품의 종류에 따라 선별되고 적절한 양으로 사용될 수 있다.In addition, the composition can be used in combination with a preservative (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate), a disinfectant (such as bleaching powder and highly bleached white powder, sodium hypochlorite), an antioxidant (butylhydroxy anisole (BHA) (Sodium hypophosphate), bleach (sodium sulfite), seasoning (sodium MSG glutamate, etc.), sweeteners (hemicellulose, cyclamate, saccharin, A food additive such as a flavor (vanillin, lactones), a swelling agent (alum, D-tartrate, potassium hydrogen), an emulsifier, a thickening agent (glue), a covering agent, a gum base agent, a foam inhibitor, and food additives. The additives may be selected and used in appropriate amounts depending on the type of food.
상기 금속 나노입자는 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 혼합양은 그의 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조시에 본 발명의 식품 조성물은 식품 또는 음료에 대하여 50 중량부 이하, 구체적으로 20 중량부 이하의 양으로 첨가될 수 있다. 그러나 건강 및 위생을 목적으로 장기간 섭취할 경우에는 상기 범위 이하의 함량을 포함할 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다.The metal nanoparticles may be added directly or together with other food or food ingredients, and may be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to its intended use (prevention, health or therapeutic treatment). Generally, the food composition of the present invention may be added in an amount of not more than 50 parts by weight, specifically not more than 20 parts by weight, based on the food or beverage, when the food or drink is prepared. However, in case of long-term ingestion for health and hygiene purposes, the active ingredient may be contained in an amount not exceeding the above range and there is no problem in terms of safety.
본 발명의 식품 조성물의 일 예로 건강음료 조성물으로 사용될 수 있으며, 이 경우 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드; 말토스, 슈크로스와 같은 디사카라이드; 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드; 자일리톨, 소르비톨, 에리트리톨 등의 당알콜일 수 있다. 감미제는 타우마틴, 스테비아 추출물과 같은 천연 감미제; 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 mL 당 일반적으로 약 0.01 ~ 0.04 g, 구체적으로 약 0.02 ~ 0.03 g이 될 수 있다.As an example of the food composition of the present invention, it can be used as a health beverage composition. In this case, various flavors or natural carbohydrates can be added as an additional ingredient such as ordinary beverages. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose, sucrose; Polysaccharides such as dextrin, cyclodextrin; Xylitol, sorbitol, erythritol, and the like. Sweeteners include natural sweeteners such as tau Martin and stevia extract; Synthetic sweetening agents such as saccharin and aspartame, and the like can be used. The ratio of the natural carbohydrate may be generally about 0.01 to 0.04 g, specifically about 0.02 to 0.03 g per 100 mL of the composition of the present invention.
상기 외에 건강음료 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산, 펙트산의 염, 알긴산, 알긴산의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올 또는 탄산화제 등을 함유할 수 있다. 그 밖에 천연 과일주스, 과일주스 음료, 또는 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 혼합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량부당 0.01 ~ 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the health beverage composition may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acid, protective colloid thickener, pH adjuster, stabilizer, Alcohols or carbonating agents, and the like. It may also contain flesh for the production of natural fruit juices, fruit juice drinks, or vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
또 다른 실시양태로서, 본 발명은 금속 나노입자를 포함하는, 항산화용 기능성 화장료 조성물을 제공한다.In another embodiment, the present invention provides a functional cosmetic composition for antioxidation comprising metal nanoparticles.
이때, "금속 나노입자"는 상기에서 설명한 바와 같다.Here, the "metal nanoparticles" are as described above.
상기 금속 나노입자를 포함하는 항산화용 화장료 조성물은 활성산소로 인하여 유발되는 피부의 노화를 예방 또는 개선시킬 수 있는 기능성 화장품의 제조에 사용될 수 있다.The antioxidant cosmetic composition containing the metal nanoparticles can be used in the production of functional cosmetics capable of preventing or improving skin aging induced by active oxygen.
상기 용어, "기능성 화장품(cosmedical, cosmeceutical)"이란 화장품에 의약품의 전문적인 치료기능이 도입되어, 일반 화장품과 달리 생리활성적인 효능, 효과가 강조된 전문적인 기능성을 갖는 제품으로서, 피부의 미백에 도움을 주는 제품, 피부 주름개선에 도움을 주는 제품, 피부를 곱게 태우거나 자외선으로부터 피부를 보호하는데 도움을 주는 제품 중에서 보건복지부령이 정하는 화장품을 의미한다. The term "cosmedical," or "cosmeceutical" refers to a cosmetic product that incorporates a special therapeutic function of a medicinal product. Unlike general cosmetics, it has a special function that emphasizes physiologically active effects and effects. Products that help to improve skin wrinkles, cosmetics prescribed by the Ordinance of the Ministry of Health and Welfare that help protect skin from burns or UV rays.
본 발명에 있어서, 상기 기능성 화장품은 다양한 기능성 화장품 중에서 항산화 활성을 나타내어 피부노화 방지에 도움을 주는 제품을 의미하고, 구체적으로 상기 금 나노입자를 유효성분으로 포함하는 피부 노화방지용 기능성 화장품이 될 수 있으나, 특별히 이에 제한되지는 않고, 상기 피부 노화방지용 기능성 화장품에 포함되는 상기 금 나노입자의 함량 역시 특별히 제한되지 않는다.In the present invention, the functional cosmetic refers to a product that exhibits antioxidative activity in various functional cosmetics to help prevent aging of the skin. Specifically, the functional cosmetics may be a functional cosmetic for preventing skin aging comprising the gold nanoparticles as an effective ingredient , And the content of the gold nanoparticles contained in the functional skin cosmetic for preventing skin aging is also not particularly limited.
본 발명의 피부 노화방지용 기능성 화장품은 상기 금 나노입자를 유효성분으로 포함하고, 통상적으로 사용되는 화장료를 추가로 함유할 수 있는데, 예를 들면 수용성 스킨제제화를 위하여 글리세롤, 프로필렌글리콜, 1,3-부틸렌글리콜, 솔비톨, 폴리에틸렌글리콜, 카르복시비닐 폴리머, 잔탄검, 카르복시메틸셀룰로오스, 하이드록시에틸셀룰로오스, 하이드록시메틸셀룰로오스, 로커스트빈검, 알란토인, 카라기난 등을 첨가할 수 있으며; 점도와 경도조절제로 밀납, 파라핀 왁스, 스테아릴알콜, 카르나우바 왁스, 칸데릴라 왁스 및 칼슘스테아레이트, 알루미늄스테아레이트, 아연스테아레이트, 위치하젤(witchhazel) 등을 사용할 수 있고; 자외선 흡수제로 부틸메톡시디벤조일메탄, 옥틸메톡시신나메이트 등을 사용할 수 있으며; 안료로는 이산화티탄, 미립자 이산화디탄, 카올린, 나이론 파우다, 탈크, 세리사이트, 마이카, 폴리메틸메타크릴레이트 등의 체질 안료와 황색산화철, 흑색산화철, 적색산화철, 울트라마린, 산화크롬, 수산화크롬 등의 착색안료를 사용할 수 있고; 보습제로 1,3-부틸렌글리콜, 농글리세린, 에틸렌글리콜 등과 키틴, 키토산, 히아론산, 하이알루로닌산, 젖산, 글리콜산 등의 천연보습 물질들을 이용할 수 있으며; 방부제로 파라옥시안식향산 에스테르류, 이미다졸리디닐우레아 등을 사용할 수 있을 뿐만 아니라, 상기한 성분들을 제품특성에 따라 1종 또는 2종이상 혼용 배합할 수도 있다.The functional cosmetic for preventing skin aging according to the present invention may further contain cosmetics conventionally used by containing the gold nanoparticles as an effective ingredient. For example, glycerol, propylene glycol, 1,3- Butylene glycol, sorbitol, polyethylene glycol, carboxyvinyl polymer, xanthan gum, carboxymethylcellulose, hydroxyethylcellulose, hydroxymethylcellulose, locust bean gum, allantoin, carrageenan and the like may be added; Paraffin wax, stearyl alcohol, carnauba wax, candelilla wax and calcium stearate, aluminum stearate, zinc stearate, and witchhazel can be used as the viscosity and hardness adjusting agent; As the ultraviolet absorber, butylmethoxydibenzoylmethane, octylmethoxycinnamate and the like can be used; Examples of the pigment include extender pigments such as titanium dioxide, fine particulate dioxides, kaolin, nylon powder, talc, sericite, mica and polymethyl methacrylate, and pigments such as yellow iron oxide, black iron oxide, red iron oxide, ultramarine, chromium oxide, Of a coloring pigment; Natural moisturizing agents such as 1,3-butylene glycol, concentrated glycerin, ethylene glycol, and chitin, chitosan, hypalonic acid, hyaluronic acid, lactic acid and glycolic acid can be used as the moisturizing agent; As the preservative, p-hydroxybenzoic acid esters, imidazolidinyl urea, and the like can be used. In addition, one or more of the above-mentioned components may be blended according to the characteristics of the product.
본 발명의 기능성 화장품은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 제한되지 않는다. 보다 상세하게는, 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 포옴, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.The functional cosmetic composition of the present invention may be prepared in any form conventionally produced in the art and may be in the form of a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, , Oil, powder foundation, emulsion foundation, wax foundation, and spray, but are not limited thereto. More specifically, it can be manufactured in the form of a soft lotion, a nutritional lotion, a nutritional cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray or a powder.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters.
본 발명의 금속 나노입자의 제조방법을 이용하면, 빠른 시간 내에 별도의 환원제 또는 안정제의 부가 없이도 크기가 균일한 금속 나노입자를 제조할 수 있고, 이처럼 제조된 금속 나노입자는 항균 활성 및 항산화 활성을 가지므로, 이를 포함하는 조성물은 산업에 유용하게 활용될 수 있다.Using the method of the present invention, metal nanoparticles of uniform size can be prepared without adding any reducing agent or stabilizer in a short period of time, and the metal nanoparticles thus produced have antimicrobial activity and antioxidant activity Therefore, a composition containing the same can be usefully used in industry.
도 1a는 합성온도에 따른 금 나노입자의 합성수준의 변화를 비교한 결과를 나타내는 그래프이다.
도 1b는 합성온도에 따른 은 나노입자의 합성수준의 변화를 비교한 결과를 나타내는 그래프이다.
도 1c는 반응시간에 따른 금 나노입자의 합성수준의 변화를 비교한 결과를 나타내는 그래프이다.
도 1d는 합성시간에 따른 은 나노입자의 합성수준의 변화를 비교한 결과를 나타내는 그래프이다.
도 1e는 금 나노입자의 합성반응 시간에 따른 합성반응물의 색도변화를 나타내는 사진이다.
도 1f는 은 나노입자의 합성반응 시간에 따른 합성반응물의 색도변화를 나타내는 사진이다.
도 2a는 금 나노입자 및 은 나노입자의 FE-TEM 분석결과를 나타내는 전자현미경 사진으로서, 좌측은 금 나노입자를 나타내고, 우측은 은 나노입자를 나타낸다.
도 2b는 금 나노입자 및 은 나노입자의 에너지 분산형 X선 분석(EDX) 결과를 나타내는 그래프로서, 상단은 금 나노입자를 나타내고, 하단은 은 나노입자를 나타낸다.
도 2c는 금 나노입자 및 은 나노입자의 원소 매핑 분석 결과를 나타내는 형광현미경 사진으로서, 상단은 금 나노입자를 나타내고, 하단은 은 나노입자를 나타낸다.
도 2d는 금 나노입자 및 은 나노입자의 XRD 분석 결과를 나타내는 그래프로서, 상단은 금 나노입자를 나타내고, 하단은 은 나노입자를 나타낸다.
도 2e는 DLS를 통해 금 나노입자의 입자크기 분석(particle size analyzer)을 수행한 결과를 나타내는 그래프이다.
도 2f는 DLS를 통해 은 나노입자의 입자크기 분석(particle size analyzer)을 수행한 결과를 나타내는 그래프이다.
도 2g는 금 나노입자 및 은 나노입자의 FTIR 분석을 수행한 결과를 나타내는 그래프로서, (A)는 은 나노입자를 나타내고, (B)는 금 나노입자를 나타내며, (C)는 금염 화합물을 나타내고, (D)는 은염 화합물을 나타내며, (E)는 흑삼 추출물을 나타낸다.
도 3a는 본 발명에서 제공하는 금 및 은 나노입자의 항산화 활성을 비교한 결과를 나타내는 그래프이다.
도 3b는 본 발명에서 제공하는 금 및 은 나노입자를 이용하여 50% DPPH 자유라디칼을 제거시 필요한 농도(IC50)를 비교한 결과를 나타내는 그래프이다.
도 4a는 대장균(E. coli)대한 본 발명의 은 나노입자의 항균활성을 나타내는 사진이다.
도 4b는 황색포도상구균(S. aureus)에 대한 본 발명의 은 나노입자의 항균활성을 나타내는 사진이다.
도 4c는 본 발명의 은 나노입자의 항균활성을 분석한 결과를 나타내는 그래프이다.
도 5a는 인간 각질형성세포(HaCaT) 및 인간 유방암(MCF-7) 세포주에 다양한 농도의 금 나노입자를 처리한 경우의 세포생존율을 측정한 결과를 나타내는 그래프이다.
도 5b는 인간 각질형성세포(HaCaT) 및 인간 유방암(MCF-7) 세포주에 다양한 농도의 은 나노입자를 처리한 경우의 세포생존율을 측정한 결과를 나타내는 그래프이다.FIG. 1A is a graph showing the results of comparison of changes in the synthesis level of gold nanoparticles according to the synthesis temperature. FIG.
FIG. 1B is a graph showing the results of comparison of changes in the synthesis level of silver nanoparticles according to the synthesis temperature. FIG.
FIG. 1C is a graph showing the results of comparing changes in the synthesis level of gold nanoparticles according to the reaction time. FIG.
FIG. 1D is a graph showing the results of comparison of changes in the synthesis level of silver nanoparticles according to the synthesis time. FIG.
FIG. 1E is a photograph showing change in chromaticity of a synthetic reaction product according to synthesis reaction time of gold nanoparticles. FIG.
FIG. 1F is a photograph showing the chromaticity change of the synthesized reaction product according to the synthesis reaction time of the silver nanoparticles. FIG.
FIG. 2A is an electron micrograph showing the results of FE-TEM analysis of gold nanoparticles and silver nanoparticles, in which gold nanoparticles are shown on the left and silver nanoparticles are shown on the right.
FIG. 2B is a graph showing energy dispersive X-ray analysis (EDX) results of gold nanoparticles and silver nanoparticles. The upper part shows gold nanoparticles and the lower part shows silver nanoparticles.
FIG. 2C is a fluorescence microscope photograph showing the result of elemental mapping analysis of gold nanoparticles and silver nanoparticles, wherein gold is shown at the top and silver nanoparticles at the bottom.
FIG. 2D is a graph showing the XRD analysis results of the gold nanoparticles and the silver nanoparticles, wherein the top shows gold nanoparticles and the bottom shows silver nanoparticles.
FIG. 2E is a graph showing the results of particle size analyzer of gold nanoparticles through DLS. FIG.
FIG. 2f is a graph showing the results of particle size analyzer of silver nanoparticles through DLS. FIG.
FIG. 2G is a graph showing the results of FTIR analysis of gold nanoparticles and silver nanoparticles, wherein (A) represents silver nanoparticles, (B) represents gold nanoparticles, (C) represents a gold salt compound , (D) represents a silver salt compound, and (E) represents a black ginseng extract.
FIG. 3A is a graph showing the results of comparing antioxidative activities of gold and silver nanoparticles provided in the present invention. FIG.
FIG. 3B is a graph showing the results of comparing concentrations (IC 50 ) required for removing 50% DPPH free radicals using the gold and silver nanoparticles provided in the present invention.
4A is a photograph showing antibacterial activity of silver nanoparticles of the present invention against E. coli .
4B is a photograph showing antimicrobial activity of silver nanoparticles of the present invention against S. aureus .
4C is a graph showing the results of analyzing the antibacterial activity of the silver nanoparticles of the present invention.
FIG. 5A is a graph showing the results of measurement of cell viability of human keratinocyte (HaCaT) and human breast cancer (MCF-7) cell lines treated with various concentrations of gold nanoparticles.
FIG. 5B is a graph showing the results of measuring cell viability of human keratinocyte (HaCaT) and human breast cancer (MCF-7) cell lines treated with various concentrations of silver nanoparticles.
이하 본 발명을 실시예를 통하여 보다 상세하게 설명한다. 그러나 이들 실시예는 본 발명을 예시적으로 설명하기 위한 것으로 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited to these examples.
실시예 1: 흑삼 추출물을 이용한 금 나노입자 또는 은 나노입자의 제조Example 1: Preparation of gold nanoparticles or silver nanoparticles using black ginseng extract
실시예Example 1-1: 흑삼 추출물의 제조 1-1: Preparation of black ginseng extract
100℃에서 3시간 백삼을 찌고 60℃에서 24시간 건조시키는 작업을 9번 반복하여 흑삼을 제조하였다. 상기 제조된 흑삼을 분쇄하여 흑삼분말을 수득하고, 5g의 흑삼분말에 100ml의 증류수를 가한 다음 30분간 가열하여 추출하였다. 추출이 종료된 후, 추출액을 와트만 여과지로 여과하여 액상성분을 수득하고, 상기 수득한 액상성분을 원심분리(10,000rpm, 10분)하여 수득한 상등액을 흑삼 추출물로 사용하였다.White ginseng was steamed at 100 ° C for 3 hours and then dried at 60 ° C for 24 hours. This operation was repeated 9 times to prepare black ginseng. The thus prepared black gum was pulverized to obtain a black gum powder, and 5 g of black gum powder was added with 100 ml of distilled water, followed by heating for 30 minutes for extraction. After the extraction was completed, the extract was filtered with a Wattman filter paper to obtain a liquid component. The supernatant obtained by centrifuging the obtained liquid component (10,000 rpm, 10 minutes) was used as a black ginseng extract.
실시예Example 1-2: 금 나노입자의 제조 1-2: Preparation of gold nanoparticles
상기 실시예 1-1에서 제조된 흑삼 추출물 5 ㎖에 증류수 25 ㎖을 가하여 반응액을 수득하고, 상기 반응액에 금염 화합물(HAuCl4-3H2O)을 최종농도 1mM가 될 때 까지 가하여 금 나노입자를 합성하였다. 반응의 진행과정은 일정 시간 간격으로 용액의 흡광도를 측정하여 모니터링하였다. 반응물에서 용액의 색변화는 금 나노입자의 형성을 나타내었다. 색 변화가 확인된 후, 반응물을 원심분리(2,000 rpm, 10분)하여 불필요한 성분을 제거하였다. 그런 다음, 합성된 나노입자를 물로 지속적으로 세척하여 정제하고, 원심분리(16,000 rpm, 15분)하여 침전물 형태의 금 나노입자를 수득하였다. 끝으로, 정제된 금 나노입자를 하룻밤동안 공기건조 시켜서, 분말형태의 금 나노입자를 제조하였다.25 ml of distilled water was added to 5 ml of the black ginseng extract prepared in Example 1-1 to obtain a reaction solution. To the reaction solution, a gold salt compound (HAuCl 4 -3H 2 O) was added until a final concentration of 1 mM was reached, Particles were synthesized. The progress of the reaction was monitored by measuring the absorbance of the solution at constant time intervals. The color change of the solution in the reaction indicated the formation of gold nanoparticles. After the color change was confirmed, the reaction product was centrifuged (2,000 rpm, 10 minutes) to remove unnecessary components. Then, the synthesized nanoparticles were continuously washed with water, purified, and centrifuged (16,000 rpm, 15 minutes) to obtain gold nanoparticles in the form of a precipitate. Finally, the purified gold nanoparticles were air-dried overnight to produce gold nanoparticles in powder form.
실시예Example 1-3: 은 나노입자의 제조 1-3: Preparation of silver nanoparticles
금염 화합물 대신에 은염 화합물(AgNO3)을 사용하는 것을 제외하고는, 상기 실시예 1-2의 방법을 사용하여 분말형태의 은 나노입자를 제조하였다.Silver nanoparticles in powder form were prepared using the method of Example 1-2 above, except that the silver salt compound (AgNO 3 ) was used instead of the gold salt compound.
실시예 1-4: 나노입자의 제조에 미치는 온도의 영향 분석EXAMPLES 1-4: Effect of temperature on the production of nanoparticles
상기 실시예 1-2 및 1-3의 나노입자 제조시에 온도의 영향을 분석하기 위하여, 상기 합성반응을 다양한 온도(23, 40, 60, 80 및 90℃)에서 수행하고, 그 결과를 분석하였다(도 1a 및 1b). 상기 분석은 UV-Vis 분광계를 사용하여 수행하였는데, 대략적으로 반응이 종료된 반응물을 소량 분주한 분주액(200㎕)을 10mm 경로길이 수정 큐벳을 가진 UV-Vis 분광계(2100Pro, Amersham, Biosciences Corp. USA)를 사용하여 300-800nm의 범위에서 스캐닝하는 방식으로 수행하였다.In order to analyze the effect of temperature on the nanoparticles of Examples 1-2 and 1-3, the synthesis reaction was carried out at various temperatures (23, 40, 60, 80 and 90 ° C) (Figs. 1A and 1B). The analysis was performed using a UV-Vis spectrometer. A small aliquot (200 μl) of the reacted reaction was dispensed into a UV-Vis spectrometer (2100Pro, Amersham, Biosciences Corp.) with a 10 mm path length correction cuvette. USA) in the range of 300-800 nm.
도 1a는 합성온도에 따른 금 나노입자의 합성수준의 변화를 비교한 결과를 나타내는 그래프이다. 도 1a에서 보듯이, 금 나노입자의 표면 플라즈몬 파장(λmax)은 548 nm에서 확인되었는데, 합성온도가 증가할수록 금 나노입자의 최대 흡수피크가 증가됨이 확인되었는 바, 합성 온도가 증가할 수록 금 나노입자가 더욱 많은 량으로 합성됨을 알 수 있었다. 특히, 60℃에서 합성된 금 나노입자의 합성수준과 80℃에서 합성된 금 나노입자의 합성수준에 큰 차이를 나타내므로, 적어도 80℃ 이상의 온도에서 합성함이 바람직함을 알 수 있었다.FIG. 1A is a graph showing the results of comparison of changes in the synthesis level of gold nanoparticles according to the synthesis temperature. FIG. As shown in FIG. 1A, the surface plasmon wavelength (λmax) of gold nanoparticles was confirmed at 548 nm. As the synthesis temperature increased, the maximum absorption peak of gold nanoparticles increased. As the synthesis temperature increased, Particles were synthesized in larger quantities. Particularly, it is found that the synthesis is preferably performed at a temperature of at least 80 ° C, since there is a large difference between the synthesis level of the gold nanoparticles synthesized at 60 ° C and the synthesis level of the gold nanoparticles synthesized at 80 ° C.
도 1b는 합성온도에 따른 은 나노입자의 합성수준의 변화를 비교한 결과를 나타내는 그래프이다. 도 1b에서 보듯이, 은 나노입자의 표면 플라즈몬 파장(λmax)은 412 nm에서 확인되었는데, 은 나노입자 역시 합성온도가 증가할수록 은 나노입자가 더욱 많은 량으로 합성됨을 알 수 있었다. 특히, 40℃에서 합성된 은 나노입자의 합성수준과 60℃에서 합성된 은 나노입자의 합성수준에 큰 차이를 나타내므로, 적어도 60℃ 이상의 온도에서 합성함이 바람직함을 알 수 있었다. FIG. 1B is a graph showing the results of comparison of changes in the synthesis level of silver nanoparticles according to the synthesis temperature. FIG. As shown in FIG. 1B, the surface plasmon wavelength (λmax) of the silver nanoparticles was confirmed at 412 nm. It was also found that the silver nanoparticles were synthesized in larger amounts as the synthesis temperature also increased. In particular, it is preferable to synthesize the silver nanoparticles at a temperature of at least 60 ° C. because the silver nanoparticles synthesized at 40 ° C. exhibit a large difference in the synthesis level and the silver nanoparticles synthesized at 60 ° C.
실시예Example 1-5: 나노입자의 제조에 미치는 반응시간의 영향 분석 1-5: Effect of reaction time on nanoparticle preparation
상기 실시예 1-2 및 1-3의 나노입자 제조시에 반응시간의 영향을 분석하기 위하여, 금 나노입자의 합성반응은 90℃에서 3, 10, 15, 20 및 25 분 동안 수행하고, 은 나노입자의 합성반응은 90℃에서 3, 4 및 4.5 시간 동안 수행하였으며, 이로부터 얻어진 금속 나노입자의 합성수준을 분석하였다(도 1c 및 1d). 상기 분석은 UV-Vis 분광계를 사용하여 수행하였다.In order to analyze the effect of the reaction time in the preparation of the nanoparticles of Examples 1-2 and 1-3, the synthesis reaction of the gold nanoparticles was carried out at 90 ° C. for 3, 10, 15, 20 and 25 minutes, The synthesis reaction of the nanoparticles was carried out at 90 DEG C for 3, 4 and 4.5 hours, and the synthesis level of the metal nanoparticles obtained therefrom was analyzed (FIGS. 1C and 1D). The analysis was carried out using a UV-Vis spectrometer.
도 1c는 반응시간에 따른 금 나노입자의 합성수준의 변화를 비교한 결과를 나타내는 그래프이다. 도 1c에서 보듯이, 금 나노입자의 표면 플라즈몬 파장(λmax)은 548 nm에서 확인되었는데, 합성시간이 증가할수록 금 나노입자의 최대 흡수피크가 증가됨이 확인되었는 바, 합성시간이 증가할 수록 금 나노입자가 더욱 많은 량으로 합성됨을 알 수 있었다. 특히, 3분동안 합성된 금 나노입자의 수준과 10분 동안 합성된 금 나노입자의 수준에 큰 차이를 나타내므로, 적어도 10분 이상의 시간 동안 합성함이 바람직함을 알 수 있었다.FIG. 1C is a graph showing the results of comparing changes in the synthesis level of gold nanoparticles according to the reaction time. FIG. As shown in FIG. 1C, the surface plasmon wavelength (λmax) of the gold nanoparticles was confirmed at 548 nm. As the synthesis time increased, the maximum absorption peak of gold nanoparticles increased. As the synthesis time increased, Particles were synthesized in larger quantities. In particular, it is preferable to synthesize the gold nanoparticles synthesized for 3 minutes and the gold nanoparticles synthesized for 10 minutes at least for 10 minutes or longer.
도 1d는 합성시간에 따른 은 나노입자의 합성수준의 변화를 비교한 결과를 나타내는 그래프이다. 도 1d에서 보듯이, 은 나노입자의 표면 플라즈몬 파장(λmax)은 412 nm에서 확인되었는데, 은 나노입자 역시 합성시간이 증가할수록 은 나노입자가 더욱 많은 량으로 합성됨을 알 수 있었다. 특히, 4시간 동안 합성된 은 나노입자의 수준과 4.5시간 동안 합성된 은 나노입자의 수준에 큰 차이를 나타내므로, 적어도 4.5시간 이상의 시간동안 합성함이 바람직함을 알 수 있었다. FIG. 1D is a graph showing the results of comparison of changes in the synthesis level of silver nanoparticles according to the synthesis time. FIG. As shown in FIG. 1d, the surface plasmon wavelength (λmax) of the silver nanoparticles was confirmed at 412 nm. As the synthesis time of the silver nanoparticles increased, the silver nanoparticles were synthesized in larger amounts. In particular, it is preferable to synthesize silver nanoparticles for at least 4.5 hours, since the silver nanoparticles synthesized for 4 hours and the silver nanoparticles synthesized for 4.5 hours are significantly different from each other.
한편, 상기 금속나노입자의 합성시 시간의 경과에 따라, 합성반응물의 색이 변화됨을 확인하였다(도 1e 및 1f).On the other hand, it was confirmed that the color of the synthetic reaction product changed with the lapse of time during the synthesis of the metal nanoparticles (FIGS. 1E and 1F).
도 1e는 금 나노입자의 합성반응 시간에 따른 합성반응물의 색도변화를 나타내는 사진이고, 도 1f는 은 나노입자의 합성반응 시간에 따른 합성반응물의 색도변화를 나타내는 사진이다. 도 1e 및 1f에서 보듯이, 금속 나노입자의 표면 플라즈몬 파장을 분석하지 않고, 반응물의 색도를 확인하는 방법을 통해, 금속 나노입자의 적절한 반응시간을 확인할 수 있음을 알 수 있었다.FIG. 1E is a photograph showing the chromaticity change of the synthetic reaction product according to the synthesis reaction time of the gold nanoparticles. FIG. 1F is a photograph showing the chromaticity change of the synthesized reaction product according to the synthesis reaction time of the silver nanoparticles. As shown in FIGS. 1E and 1F, it was found that the appropriate reaction time of the metal nanoparticles can be confirmed by a method of confirming the chromaticity of the reactant without analyzing the surface plasmon wavelength of the metal nanoparticles.
실시예 2: 금 나노입자 또는 은 나노입자의 구조적 특성 분석Example 2: Structural characterization of gold nanoparticles or silver nanoparticles
실시예Example 2-1: FE- 2-1: FE- TEMTEM 분석 analysis
FE-TEM은 금속 나노 입자의 금속 코어 크기를 결정하는데 사용하는 반면, DLS는 나노 입자의 캡핑층을 포함하는 유체 역학적 크기(hydrodynamic size, Z-average)를 평가하는데 사용된다. 상기 FE-TEM 측정을 통해 금 나노입자와 은 나노입자의 크기를 분석하였다(도 2a). The FE-TEM is used to determine the metal core size of the metal nanoparticles, while DLS is used to evaluate the hydrodynamic size (Z-average), including the capping layer of the nanoparticles. The sizes of the gold nanoparticles and silver nanoparticles were analyzed through the FE-TEM measurement (FIG. 2A).
도 2a는 금 나노입자 및 은 나노입자의 FE-TEM 분석결과를 나타내는 전자현미경 사진으로서, 좌측은 금 나노입자를 나타내고, 우측은 은 나노입자를 나타낸다. 도 2a에서 보듯이, 금 나노입자와 은 나노입자는 공통적으로 5 내지 30 nm의 변동되는 크기를 가지는 구형임을 확인하였다.FIG. 2A is an electron micrograph showing the results of FE-TEM analysis of gold nanoparticles and silver nanoparticles, in which gold nanoparticles are shown on the left and silver nanoparticles are shown on the right. As shown in FIG. 2A, it was confirmed that gold nanoparticles and silver nanoparticles were generally spherical with a varying size of 5 to 30 nm.
실시예Example 2-2: 에너지 분산형 X선 분석( 2-2: Energy dispersive X-ray analysis EDXEDX ) 및 원소 ) And element 매핑Mapping 분석 analysis
EDX는 200 kV에서 정제된 나노입자 1 방울을 탄소 코팅 구리 그리드에 놓고, 60℃의 오븐에서 건조시킨 후, 이를 대상으로 JEM-2100F 전자현미경을 사용하여 수행하였다(도 2b). EDX was prepared by placing one drop of the purified nanoparticles at 200 kV on a carbon coated copper grid and drying in an oven at 60 DEG C, using a JEM-2100F electron microscope (FIG. 2B).
도 2b는 금 나노입자 및 은 나노입자의 에너지 분산형 X선 분석(EDX) 결과를 나타내는 그래프로서, 상단은 금 나노입자를 나타내고, 하단은 은 나노입자를 나타낸다. 도 2b에서 보듯이, 각각 2.2 keV 과 3.3 keV에서 금속 금과 은의 특징적 피크의 존재를 확인하였다FIG. 2B is a graph showing energy dispersive X-ray analysis (EDX) results of gold nanoparticles and silver nanoparticles. The upper part shows gold nanoparticles and the lower part shows silver nanoparticles. As shown in FIG. 2B, the existence of characteristic peaks of metallic gold and silver was confirmed at 2.2 keV and 3.3 keV, respectively
또한, 금 나노입자와 은 나노입자의 원소 매핑 분석을 통해 각 금속 나노입자의 순도를 확인하고, 상기 EDX 결과와 원소 매핑 분석 결과를 조합하여 이들 나노입자의 분포를 확인하였다(도 2c). In addition, the purity of each metal nano-particle was confirmed through elemental mapping analysis of gold nanoparticles and silver nanoparticles, and the distribution of these nanoparticles was confirmed by combining the EDX results and the element mapping analysis results (FIG. 2C).
도 2c는 금 나노입자 및 은 나노입자의 원소 매핑 분석 결과를 나타내는 형광현미경 사진으로서, 상단은 금 나노입자를 나타내고, 하단은 은 나노입자를 나타낸다.FIG. 2C is a fluorescence microscope photograph showing the result of elemental mapping analysis of gold nanoparticles and silver nanoparticles, wherein gold is shown at the top and silver nanoparticles at the bottom.
실시예Example 2-3: 2-3: XRDXRD 분석 analysis
XRD 분석은 X-ray 회절계를 사용하여 수행되었는데, 상기 X-ray 회절계는 40 kV, 40 mA, 1.54 A의 CuK α 조사, 6°/min의 스캔속도 및 0.02°의 스텝 크기에서 작동시켰다. 시료를 20-80°범위에서 2θ 이상 스캔하였다. 상기 금속 나노입자 결정체의 평균 크기는 Debye-Scherrer 수식에 의해 산출하였다: XRD analysis was performed using an X-ray diffractometer, which operated at 40 kV, 40 mA, 1.54 A CuK alpha irradiation, a scan rate of 6 DEG / min and a step size of 0.02 DEG . The sample was scanned over 2? Over a range of 20-80 °. The average size of the metal nanoparticle crystals was calculated by the Debye-Scherrer equation:
D = 0.9λ/β cos θ, D = 0.9λ/β cos θ, D = 0.9? /? Cos?, D = 0.9? /? Cos?
이때 D는 nm당 미결정의 크기이고, λ는 CuK nm당 α 조사의 파장이며, β는 라디안당 FWHM(full width at half maximum) 이고, θ는 라디안당 Bragg angle의 중간값이다. XRD 스펙트럼은 합성물질에 의해 나타나는 결정성의 동정을 위해 기록하였다(도 2d). Where D is the size of the microcrystalline per nm, λ is the wavelength of α irradiation per CuK nm, β is the full width at half maximum (FWHM) per radian, and θ is the median of the Bragg angle per radian. The XRD spectrum was recorded for identification of the crystallinity exhibited by the synthetic material (Fig. 2D).
도 2d는 금 나노입자 및 은 나노입자의 XRD 분석 결과를 나타내는 그래프로서, 상단은 금 나노입자를 나타내고, 하단은 은 나노입자를 나타낸다. 도 2d에서 보듯이, 금 나노입자(38.33°, 44.31°, 64.90° 및 77.69°에서 측정)와 은 나노입자(38.22°, 44.24°, 64.26° 및 77.69°에서 측정)의 특성 피크는 브래그 반사의 래티스면 (111), (200), (220) 및 (311)의 회절 피크로 연동됨을 확인하였다.FIG. 2D is a graph showing the XRD analysis results of the gold nanoparticles and the silver nanoparticles, wherein the top shows gold nanoparticles and the bottom shows silver nanoparticles. The characteristic peaks of gold nanoparticles (measured at 38.33 °, 44.31 °, 64.90 ° and 77.69 °) and silver nanoparticles (measured at 38.22 °, 44.24 °, 64.26 ° and 77.69 °) It was confirmed that the diffraction peaks of the lattice planes (111), (200), (220) and (311) interlocked with each other.
실시예Example 2-4: 입자크기 분석(particle size analyzer) 2-4: Particle size analyzer
증류수에 현탁된 나노입자의 입자크기 분포는 DLS(dynamic light scattering)에 의해 수득하였다. 히드로다이나믹 (Z-average) 직경과 PDI(polydispersity index)는 25℃에서 평가하였다. 1.3328의 굴절률, 0.8878의 점도 및 78.3의 유전상수를 갖는 순수 물의 분산매질을 대조군으로 사용하였다(도 2e 및 2f). The particle size distribution of the nanoparticles suspended in distilled water was obtained by dynamic light scattering (DLS). The hydrodynamic (Z-average) diameter and PDI (polydispersity index) were evaluated at 25 占 폚. A dispersion medium of pure water having a refractive index of 1.3328, a viscosity of 0.8878 and a dielectric constant of 78.3 was used as a control (Figs. 2e and 2f).
도 2e는 DLS를 통해 금 나노입자의 입자크기 분석(particle size analyzer)을 수행한 결과를 나타내는 그래프이다. 도 2e에서 보듯이, 금 나노입자의 Z-평균 크기는 273.40nm이며, PDI 값은 0.13이었는데, 이는 생합성된 금 나노입자가 속성상 보통 정도의 다분산임을 암시한다. FIG. 2E is a graph showing the results of particle size analyzer of gold nanoparticles through DLS. FIG. As shown in FIG. 2E, the Z-average size of the gold nanoparticles was 273.40 nm and the PDI value was 0.13, suggesting that the biosized gold nanoparticles are moderately polydisperse in nature.
도 2f는 DLS를 통해 은 나노입자의 입자크기 분석(particle size analyzer)을 수행한 결과를 나타내는 그래프이다. 도 2f에서 보듯이, 은 나노입자의 Z-평균 크기가 213.20nm이며, PDI 값이 0.10임을 보였는데, 이는 생합성된 은 나노입자가 좁은 분포를 갖는 단분산임을 시사한다.FIG. 2f is a graph showing the results of particle size analyzer of silver nanoparticles through DLS. FIG. As shown in FIG. 2F, the Z-average size of the silver nanoparticles was 213.20 nm and the PDI value was 0.10, suggesting that the biosynthesized silver nanoparticles are monodisperse with a narrow distribution.
실시예Example 2-5: 2-5: FTIRFTIR (Fourier Transform-(Fourier Transform- Infrared spectrometerInfrared spectrometer ) 분석) analysis
금 나노입자 및 은 나노입자의 FTIR 측정은 4000-450 cm-1 및 4 cm-1의 해상도로 PerkinElmer Spectrum One FTIR spectrometer를 사용하여 수행하였다(도 2g).FTIR measurements of gold nanoparticles and silver nanoparticles were performed using a PerkinElmer Spectrum One FTIR spectrometer at a resolution of 4000-450 cm -1 and 4 cm -1 (Figure 2g).
도 2g는 금 나노입자 및 은 나노입자의 FTIR 분석을 수행한 결과를 나타내는 그래프로서, (A)는 은 나노입자를 나타내고, (B)는 금 나노입자를 나타내며, (C)는 금염 화합물을 나타내고, (D)는 은염 화합물을 나타내며, (E)는 흑삼 추출물을 나타낸다. FIG. 2G is a graph showing the results of FTIR analysis of gold nanoparticles and silver nanoparticles, wherein (A) represents silver nanoparticles, (B) represents gold nanoparticles, (C) represents a gold salt compound , (D) represents a silver salt compound, and (E) represents a black ginseng extract.
도 2g에서 보듯이, 흑삼 뿌리 추출물의 FTIR 스펙트럼은 3428cm-1, 1630cm-1 및 1027cm-1에서 강한 피크를 나타내었는데, 이는 각각 폴리페닐렌 플라보노이드에서의 OH기의 O-H 신축진동, 아미노산 또는 단백질 잔기로 인한 3차 아민과 관련된 C=O 신축 진동, 및 플라보노이드 에스테르의 C-O 신축에 해당된다. 또한, 2927cm-1에서의 공유된 중간정도의 피크는 메틸기의 C-H 신축 진동을 나타낸다. As shown in FIG. 2g, the FTIR spectrum of the black ginseng root extract showed strong peaks at 3428 cm -1 , 1630 cm -1 and 1027 cm -1 , respectively, indicating the OH stretching vibration of the OH group in the polyphenylene flavonoid, the amino acid or protein residue , C = O stretching vibration associated with tertiary amines, and CO expansion of flavonoid esters. In addition, the shared median peak at 2927 cm -1 represents the CH stretching vibration of the methyl group.
한편, 은 나노입자 및 금 나노입자의 FTIR 스펙트럼은 강도는 다르지만 흑삼 뿌리 추출물 스펙트럼과 유사한 피크를 나타내었다. 구체적으로, 은 나노입자는 금 나노입자(3421, 2918, 1637 및 1021cm-1) 주위의 생분자보다 더 약한 밴드(3422, 2917, 1635 및 1025cm-1)를 나타내었다. On the other hand, the FTIR spectra of the silver nanoparticles and the gold nanoparticles showed peaks similar to those of the black ginseng root extract although their intensities were different. Specifically, the nano-particles exhibited a gold nanoparticle (3421, 2918, 1637 and 1021cm -1) weaker than the band around the biomolecule (3422, 2917, 1635 and 1025cm -1).
상기 FTIR 스펙트럼 분석을 통하여, 흑삼 뿌리 추출물 내의 폴리페닐렌 플라보노이드, 단백질 및 플라보노이드 에스테르는 생합성된 금 및 은 나노입자의 환원 및 캡핑의 역할을 할 것으로 분석되었다.Through the FTIR spectral analysis, polyphenylene flavonoids, proteins and flavonoid esters in black ginseng root extracts were analyzed to be responsible for the reduction and capping of biosubstituted gold and silver nanoparticles.
실시예Example 2-6: 안정성 분석 2-6: Stability Analysis
실험실 수준에서 금 나노입자 및 은 나노입자의 안정성을 평가하였다.The stability of gold nanoparticles and silver nanoparticles was evaluated at the laboratory level.
구체적으로, 금 나노입자 및 은 나노입자의 안정성을 증류수, 20 mM glycine-HCl 완충액(pH 2.0), citric acid-sodium citrate 완충액(pH 5.0), sodium phosphate 완충액(pH 7.0), Tris-HCl 완충액(pH 8.0), 5% NaCl 용액, 10% NaCl 용액 및 5% BSA 용액에서 시험하였다. 금속 나노입자 용액 100 ㎕에 상기 각 용액 900 ㎕를 가하고, 37 ℃에서 반응시켰다. UV-Vis 분광광도계를 사용하여 표면 플라스몬에서 유의한 차이가 없으면, 금 및 은 나노입자가 안정성을 갖는 것으로 확인하였다.Specifically, the stability of gold nanoparticles and silver nanoparticles was measured by using distilled water, 20 mM glycine-HCl buffer (pH 2.0), citric acid-sodium citrate buffer (pH 5.0), sodium phosphate buffer (pH 7.0), Tris- pH 8.0), 5% NaCl solution, 10% NaCl solution and 5% BSA solution. 900 쨉 l of each of the above solutions was added to 100 쨉 l of the metal nanoparticle solution, followed by reaction at 37 째 C. The gold and silver nanoparticles were found to be stable if there was no significant difference in surface plasmons using a UV-Vis spectrophotometer.
그 결과, 금 나노입자와 은 나노입자의 DW, pH2, pH7, pH8, 10% NaCl 및 5% BSA 용액에서의 표면 플라즈몬 파장은 37℃에서 반응 1일 후 최소파장이동(0-5 nm)을 보였다. 금 나노입자의 경우에는 한달 이후에도 모든 소정의 조건에서 표면 플라즈몬 파장의 이동은 없었다. 또한, 은 나노입자의 경우에는 한달 이후에 DW 과5% BSA에서 장기적으로 안정함을 보였다. 이러한 결과는 금 나노입자와 은 나노입자가 그대로인 생리적 pH 조건에서 안정성을 나타냄을 시사하는 것으로 분석되었다.As a result, the surface plasmon wavelengths of DW,
실시예Example 3: 금 나노입자 또는 은 나노입자의 기능적 특성 분석 3: Functional characterization of gold nanoparticles or silver nanoparticles
실시예Example 3-1: 금 나노입자와 은 나노입자의 항산화 활성분석 3-1: Antioxidant activity analysis of gold nanoparticles and silver nanoparticles
DPPH(1,1- diphenyl-2-picrylhydrazyl)의 자유 라디칼 제거 활성을 이용하여, 금 나노입자(BGAuNPs), 은 나노입자(BGgNPs), 금염 화합물 및 은염 화합물의 항산화 활성을 확인하였다. DPPH의 0.1 mM 메탄올 용액 160 ㎕에 다양한 농도(2-20 ㎍/㎖)의 시료 용액 40 ㎕를 부가하였다. 양성 대조군으로는 갈산(GA)을 사용하였다. 30분 후, 517 nm에서 흡광도를 측정하고, 이를 하기 식에 적용하여 자유라디칼 제거활성을 산출한 후, 이를 농도별로 비교하였다(도 3a). 이때, 음성대조군으로는 갈릭산(GA)을 사용하고, 양성대조군으로는 흑삼 추출물(BG)을 사용하였다.The antioxidant activity of gold nanoparticles (BGAuNPs), silver nanoparticles (BGgNPs), gold salt compounds and silver salt compounds was confirmed using the free radical scavenging activity of DPPH (1,1-diphenyl-2-picrylhydrazyl). To 160 μl of a 0.1 mM methanol solution of DPPH, 40 μl of a sample solution of various concentrations (2-20 μg / ml) was added. Galactic acid (GA) was used as a positive control. After 30 minutes, the absorbance at 517 nm was measured, and the free radical scavenging activity was calculated by applying the following equation, and the concentration was compared according to the concentration (FIG. 3A). At this time, gallic acid (GA) was used as a negative control group and black ginseng extract (BG) was used as a positive control group.
자유라디칼 제거활성 = [(대조군 흡광도 - 시료 흡광도)/ 대조군 흡광도] × 100Free radical scavenging activity = [(control absorbance - sample absorbance) / control absorbance] × 100
이때, 시료 흡광도는 나노입자를 가한 DPPH 용액에서 측정하고, 대조군 흡광도는 나노입자를 가하지 않은 DPPH 용액에서 측정하였다. At this time, sample absorbance was measured in DPPH solution added with nanoparticles, and control absorbance was measured in DPPH solution not added nanoparticles.
도 3a는 본 발명에서 제공하는 금 및 은 나노입자의 항산화 활성을 비교한 결과를 나타내는 그래프이다. 도 3a에서 보듯이, 본 발명에서 제공하는 은 나노입자는 흑삼 추출물과 유사한 수준의 항산화 활성을 나타내었고, 본 발명에서 제공하는 금 나노입자는 은 나노입자에 비하여 다소 낮은 수준의 항산화 활성을 나타내었으나, 은염 화합물 또는 금염 화합물에 비하여는 현저하게 높은 수준의 항산화 활성을 나타냄을 확인하였다.FIG. 3A is a graph showing the results of comparing antioxidative activities of gold and silver nanoparticles provided in the present invention. FIG. As shown in FIG. 3A, the silver nanoparticles provided by the present invention showed antioxidative activity similar to that of the black ginseng extract, and the gold nanoparticles provided by the present invention showed a somewhat lower antioxidative activity than the silver nanoparticles , A silver salt compound or a gold salt compound.
한편, 상기 항산화 활성을 나타내는 각 시료의 50% DPPH 자유라디칼을 제거하는데 필요한 시료의 농도를 나타내는 IC50 수치를 비교하였다(도 3b). On the other hand, IC 50 values indicating the concentration of the sample required to remove the 50% DPPH free radical of each sample showing the antioxidative activity were compared (Fig. 3B).
도 3b는 본 발명에서 제공하는 금 및 은 나노입자를 이용하여 50% DPPH 자유라디칼을 제거시 필요한 농도(IC50)를 비교한 결과를 나타내는 그래프이다. 도 3b에서 보듯이, IC50 값은 대조군으로 사용된 갈릭산이나 흑삼 추출물 보다도 본 발명에서 제공하는 은 나노입자가 가장 높은 수준을 나타내었고, 금 나노입자 역시 갈릭산과 흑삼 추출물 보다 다소 높은 수준을 나타냄을 확인하였다.FIG. 3B is a graph showing the results of comparing concentrations (IC 50 ) required for removing 50% DPPH free radicals using the gold and silver nanoparticles provided in the present invention. As shown in FIG. 3B, the IC 50 value showed the highest level of the silver nanoparticles provided by the present invention and the gold nanoparticles were somewhat higher than those of the gallic acid and black ginseng extracts, as compared with the gallic acid and black ginseng extracts used as the control group. Respectively.
실시예Example 3-2: 은 나노입자의 항균활성 분석 3-2: Antimicrobial activity analysis of silver nanoparticles
공지된 디스크 확산법을 사용하여 MHA(Mueller-Hinton agar) 플레이트에서 대장균(E. coli)과 황색포도상구균(S. aureus)에 대한 은 나노입자의 항균활성을 분석하였다. 상기 분석법에 있어서, MHA 플레이트에 0.1의 밀도로 LB 배지에서 배양된 시험균주 100 ㎕를 도말하고 하룻밤 동안 배양하였다. 대조군으로서, 네오마이신의 표준 항균 디스크를 사용하였다. 다음으로, 멸균 종이 디스크에 다양한 농도(15, 30 및 45 ㎍/disc)로 신선한 은 나노입자 용액을 흡수시켰다. 상기 플레이트를 37℃에서 24시간 동안 배양하였다. 배양이 종료된 후, 각 디스크 주위의 억제영역을 비교하였다(도 4a 내지 4c).The antimicrobial activity of silver nanoparticles against E. coli and S. aureus on an MHA (Mueller-Hinton agar) plate was analyzed using a known disk diffusion method. In this assay, 100 μl of the test strain cultured in LB medium at a density of 0.1 in MHA plate was plated and incubated overnight. As a control, a standard antimicrobial disk of neomycin was used. Next, fresh silver nanoparticle solutions were absorbed into sterile paper disks at various concentrations (15, 30 and 45 / / disc). The plate was incubated at 37 DEG C for 24 hours. After incubation was terminated, the inhibition regions around each disk were compared (Figs. 4A-4C).
도 4a는 대장균(E. coli)대한 본 발명의 은 나노입자의 항균활성을 나타내는 사진이고, 도 4b는 황색포도상구균(S. aureus)에 대한 본 발명의 은 나노입자의 항균활성을 나타내는 사진이며, 도 4c는 본 발명의 은 나노입자의 항균활성을 분석한 결과를 나타내는 그래프이다.FIG. 4A is a photograph showing the antibacterial activity of silver nanoparticles of the present invention against E. coli , FIG. 4B is a photograph showing antibacterial activity of silver nanoparticles of the present invention against S. aureus And FIG. 4C is a graph showing the results of analyzing the antibacterial activity of silver nanoparticles of the present invention.
도 4a 내지 4c에서 보듯이, 본 발명에서 제공하는 은 나노입자는 그람음성균에 속하는 대장균은 물론 그람양성균에 속하는 황색포도상구균에 대하여도 항균활성을 나타내고, 이러한 항균활성은 농도 의존적으로 증가되는 양상을 나타냄을 확인하였다.As shown in FIGS. 4A to 4C, the silver nanoparticles provided in the present invention exhibit antimicrobial activity against Staphylococcus aureus belonging to Gram-positive bacteria as well as Escherichia coli belonging to Gram-negative bacteria, and the antibacterial activity is increased in a concentration- Respectively.
실시예Example 3-3: 금 나노입자와 은 나노입자의 세포독성 분석 3-3: Cytotoxicity analysis of gold nanoparticles and silver nanoparticles
인간 각질형성세포(HaCaT) 및 인간 유방암(MCF-7) 세포주를 입수하였다. 상기 세포주를 공지된 방법에 따라 10% FBS와 1% 페니실린/스트렙토마이신을 포함하는 DMEM 배지에 접종하고, 37℃ 및 5% CO2의 조건에서 배양하였다. 상기 배양된 각 세포에 1, 10 및 100㎍/㎖의 농도로 본 발명에서 제공하는 금 나노입자 또는 은 나노입자를 가하고, 다시 72시간 동안 배양한 다음, 이들 세포의 생존율을 MTT 분석법으로 측정하였다(도 5a 및 5b). 이때, 대조군으로는 금 나노입자 또는 은 나노입자를 처리하지 않은 세포주를 사용하였다.Human keratinocyte (HaCaT) and human breast cancer (MCF-7) cell lines were obtained. The cell line was inoculated into a DMEM medium containing 10% FBS and 1% penicillin / streptomycin according to a known method and cultured at 37 ° C and 5% CO 2 . The gold nanoparticles or silver nanoparticles of the present invention were added to each of the cultured cells at a concentration of 1, 10 and 100 μg / ml, cultured for another 72 hours, and then the viability of these cells was measured by MTT assay (Figs. 5A and 5B). At this time, as a control group, a cell line not treated with gold nanoparticles or silver nanoparticles was used.
도 5a는 인간 각질형성세포(HaCaT) 및 인간 유방암(MCF-7) 세포주에 다양한 농도의 금 나노입자를 처리한 경우의 세포생존율을 측정한 결과를 나타내는 그래프이다. 도 5a에서 보듯이, 본 발명에서 제공하는 금 나노입자는 대량으로 처리하여도 세포에 어떠한 영향을 나타내지 않음을 확인하였다.FIG. 5A is a graph showing the results of measurement of cell viability of human keratinocyte (HaCaT) and human breast cancer (MCF-7) cell lines treated with various concentrations of gold nanoparticles. As shown in FIG. 5A, it was confirmed that the gold nanoparticles provided by the present invention had no effect on the cells even when treated in a large amount.
따라서, 본 발명의 금 나노입자는 세포독성을 전혀 나타내지 않음을 알 수 있었다.Therefore, it was found that the gold nanoparticles of the present invention did not show cytotoxicity at all.
도 5b는 인간 각질형성세포(HaCaT) 및 인간 유방암(MCF-7) 세포주에 다양한 농도의 은 나노입자를 처리한 경우의 세포생존율을 측정한 결과를 나타내는 그래프이다. 도 5b에서 보듯이, 본 발명에서 제공하는 은 나노입자는 금 나노입자와는 달리 대량으로 처리한 경우에는 세포의 생존율을 감소시키는 효과를 나타냄을 확인하였다.FIG. 5B is a graph showing the results of measuring cell viability of human keratinocyte (HaCaT) and human breast cancer (MCF-7) cell lines treated with various concentrations of silver nanoparticles. As shown in FIG. 5B, it was confirmed that the silver nanoparticles provided by the present invention had an effect of reducing the survival rate of cells when treated in a large amount, unlike the gold nanoparticles.
Claims (19)
A composition for the preparation of metal nanoparticles, comprising a black ginseng extract as an active ingredient.
상기 금속 나노입자는 금 나노입자 또는 은 나노입자인 것인, 조성물.
The method according to claim 1,
Wherein the metal nanoparticles are gold nanoparticles or silver nanoparticles.
상기 추출물은 흑삼을 물, C1 내지 C4의 알코올 및 이들의 혼합 용매로 이루어진 군으로부터 선택되는 용매로 추출하여 수득한 것인, 조성물.
The method according to claim 1,
Wherein the extract is obtained by extracting black ginseng with a solvent selected from the group consisting of water, C1 to C4 alcohols and mixed solvents thereof.
A method for producing metal nanoparticles, comprising: reacting the composition of claim 1 with a metal precursor to obtain a reaction product comprising metal nanoparticles.
상기 금속 전구체는 환원반응에 의해 금속 나노입자를 형성할 수 있는 금속염 화합물인 것인, 방법.
5. The method of claim 4,
Wherein the metal precursor is a metal salt compound capable of forming metal nanoparticles by a reduction reaction.
상기 금속염 화합물은 금염 화합물 또는 은염 화합물인 것인, 방법.
6. The method of claim 5,
Wherein the metal salt compound is a gold salt compound or a silver salt compound.
상기 금염 화합물은 테트라클로로금(III)산(HAuCl4), NaAuCl3, AuCl3 및 이들의 조합으로 구성되는 군으로부터 선택되는 화합물인 것인, 방법.
The method according to claim 6,
Wherein the gold salt compound is a compound selected from the group consisting of tetrachloro gold (III) acid (HAuCl 4 ), NaAuCl 3 , AuCl 3, and combinations thereof.
상기 은염 화합물은 AgBF4, AgCF3SO3, AgClO4, AgNO3, AgPF6, Ag(CF3COO) 및 이들의 조합으로 구성되는 군으로부터 선택되는 화합물인 것인, 방법.
The method according to claim 6,
Wherein the silver salt compound is a compound selected from the group consisting of AgBF 4 , AgCF 3 SO 3 , AgClO 4 , AgNO 3 , AgPF 6 , Ag (CF 3 COO), and combinations thereof.
상기 반응에 사용되는 금속 전구체의 농도는 0.01 내지 100mM인 것인, 방법.
5. The method of claim 4,
Wherein the concentration of the metal precursor used in the reaction is 0.01 to 100 mM.
상기 반응은 10 내지 100℃에서 수행되는 것인, 방법.
5. The method of claim 4,
Wherein the reaction is carried out at 10 to < RTI ID = 0.0 > 100 C. < / RTI >
상기 단계는 상기 조성물과 금염 화합물을 1분 내지 1시간 동안 반응시켜서 금 나노입자를 포함하는 반응산물을 수득하는 것인, 방법.
5. The method of claim 4,
Wherein said step of reacting said composition with a gold salt compound for 1 minute to 1 hour to obtain a reaction product comprising gold nanoparticles.
상기 단계는 상기 조성물과 은염 화합물을 30분 내지 7시간 동안 반응시켜서 은 나노입자를 포함하는 반응산물을 수득하는 것인, 방법.
5. The method of claim 4,
Wherein said step of reacting said composition with a silver salt compound for 30 minutes to 7 hours to obtain a reaction product comprising silver nanoparticles.
상기 방법은 상기 반응산물을 원심분리하여 금속 나노입자를 회수하는 단계를 추가로 포함하는 것인, 방법.
5. The method of claim 4,
Wherein the method further comprises centrifuging the reaction product to recover the metal nanoparticles.
A metal nanoparticle produced by the method of any one of claims 4 to 13.
A composition for antimicrobial use, comprising the metal nanoparticles of claim 14.
상기 조성물은 스테피로코커스(Staphylococcus) 속 미생물 또는 에스케리치아(Escherichia) 속 미생물에 대해 항균 활성을 가지는 것인, 조성물.
16. The method of claim 15,
Wherein the composition has an antimicrobial activity against microorganisms belonging to the genus Staphylococcus or Escherichia genus.
A pharmaceutical composition for antioxidation comprising the metal nanoparticles of claim 14.
A health food composition for antioxidation comprising the metal nanoparticles of claim 14.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160127842A KR101882849B1 (en) | 2016-10-04 | 2016-10-04 | A composition for producing metal nanoparticles comprising black ginseng extracts and the use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160127842A KR101882849B1 (en) | 2016-10-04 | 2016-10-04 | A composition for producing metal nanoparticles comprising black ginseng extracts and the use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20180037650A true KR20180037650A (en) | 2018-04-13 |
KR101882849B1 KR101882849B1 (en) | 2018-07-31 |
Family
ID=61974147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160127842A KR101882849B1 (en) | 2016-10-04 | 2016-10-04 | A composition for producing metal nanoparticles comprising black ginseng extracts and the use thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101882849B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021009443A1 (en) * | 2019-07-16 | 2021-01-21 | Torskal | Gold nanoparticles comprising a plant extract and their cosmetic use |
WO2021080357A1 (en) * | 2019-10-23 | 2021-04-29 | 고려대학교 산학협력단 | Antibiotic silver nanoparticles using tomato extract, and method for producing same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100842070B1 (en) * | 2007-04-09 | 2008-06-30 | 박준원 | Nano platinum ginsenoside particle and production method thereof |
KR20140043954A (en) * | 2012-09-21 | 2014-04-14 | 광주과학기술원 | Ginseng extract-metallic salts nano particle complex and preparation method thereof |
-
2016
- 2016-10-04 KR KR1020160127842A patent/KR101882849B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100842070B1 (en) * | 2007-04-09 | 2008-06-30 | 박준원 | Nano platinum ginsenoside particle and production method thereof |
KR20140043954A (en) * | 2012-09-21 | 2014-04-14 | 광주과학기술원 | Ginseng extract-metallic salts nano particle complex and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
Ragavendran Abbai 외 8명. Green synthesis of multifunctional silver and gold nanoparticles from the oriental herbal adaptogen: Siberian ginseng. Vol. 2016, 2016년 7월 11일, pp. 3131-3143 * |
Singh, Priyanka 외 5명. Biogenic silver and gold nanoparticles synthesized using red ginseng root extract, and their applications. Artificial cells, nanomedicine, and biotechnology. Vol. 44, No. 3, 2015* * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021009443A1 (en) * | 2019-07-16 | 2021-01-21 | Torskal | Gold nanoparticles comprising a plant extract and their cosmetic use |
FR3098713A1 (en) * | 2019-07-16 | 2021-01-22 | Torskal | GOLD NANOPARTICLES CONTAINING A PLANT EXTRACT AND THEIR COSMETIC USE |
WO2021080357A1 (en) * | 2019-10-23 | 2021-04-29 | 고려대학교 산학협력단 | Antibiotic silver nanoparticles using tomato extract, and method for producing same |
Also Published As
Publication number | Publication date |
---|---|
KR101882849B1 (en) | 2018-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5878023B2 (en) | AGE production inhibitor | |
US11648208B2 (en) | Nano complex comprising a nano drug delivery matrix; and a ginseng extract or a ginsenoside isolated therefrom | |
JP5783784B2 (en) | Nitric oxide production inhibitor | |
KR20170085641A (en) | Composition for producing a metal nanoparticle comprising ginseng extract and use thereof | |
JP5571280B2 (en) | Sebum production promoter | |
KR101882849B1 (en) | A composition for producing metal nanoparticles comprising black ginseng extracts and the use thereof | |
Chainpure et al. | A study of carica papaya concerning it's ancient and Traditional uses-recent advances and modern Applications for improving the milk secretion in Lactating womens | |
TWI523655B (en) | Metal ion nanoclusters | |
JP2024061845A (en) | AGE production inhibitor | |
KR101897868B1 (en) | A composition for producing metal nanoparticles comprising ginseng berry extracts and the use thereof | |
KR101917567B1 (en) | A composition for producing metal nanoparticles comprising Siberian ginseng extracts and the use thereof | |
JP2006265219A (en) | Diet composition | |
KR101971393B1 (en) | Composition for producing a metal nanoparticle comprising ginseng extract and use thereof | |
KR20170131746A (en) | A composition for producing metal nanoparticles comprising Siberian ginseng extracts and the use thereof | |
JP2014185100A (en) | AGE production inhibitor | |
JP4573611B2 (en) | Aureobasidium culture | |
WO2015022909A1 (en) | Ghg-containing composition and fat absorption inhibitor using same | |
KR101822324B1 (en) | Composition, dermatological preparation, cosmetic, and food and beverage | |
KR101840928B1 (en) | A method for producing gold nanoparticles using Lactobacillus genus microorganisms and the use thereof | |
KR101902846B1 (en) | Glabridin-Zein complex nanoparticle, manufacturing method thereof and use thereof | |
KR20170008636A (en) | Levan-Ceria Nanoparticle Complex | |
JP2006131916A (en) | Antioxidant, and food and cosmetics using it | |
JP2009107957A (en) | Water-retaining composition | |
JP6516246B2 (en) | Expression promoter of filaggrin and involucrin | |
JP2012072078A (en) | Melanogenesis inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |